Note: Descriptions are shown in the official language in which they were submitted.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
METHOD FOR PRODUCING A COMPOUND OF INTEREST
IN A FILAMENTOUS FUNGAL CELL
Field of the invention
The present invention relates to a method for producing a compound of interest
in
a filamentous fungal cell, wherein the nucleotide sequence encoding the
compound of
interest and/or control nucleotide sequences operatively associated thereto
have been
modified to get improved expression of the nucleotide sequence encoding the
compound
of interest and/or improved production of the compound of interest.
Background of the invention
The present invention relates to improved methods for producing a compound of
interest. Numerous approaches have been applied to date in generating strains
for
protein over-expression and/or production. This includes, but is not limited
to, making
strains with multi-copies of the gene encoding the compound of interest and
applying
strong promoter sequences.
Each specific amino acid is encoded by a minimum of one codon and a
maximum of six codons. Prior research has shown that codon usage in genes
encoding
the cell's polypeptides is biased among species (Kanaya, S, Y. Yamada, Y. Kudo
and T.
Ikemura (1999) Studies of codon usage and tRNA genes at 18 unicellular
organisms and
quantification of Bacillus subtilis tRNAs: gene expression level and species-
specific
diversity of codon usage based on multivariate analysis. Gene 238:143-155).
Prior
publications disclose optimization of codon use in a given host cell to
improve polypeptide
production (as example see WO 97/11086). More specifically, WO 03/70957
describes
optimized codon use in filamentous fungi for producing plant polypeptides. In
all these
cases of 'classic' codon optimization, a native codon has been substituted by
the most
frequent codon from a reference set of genes, whereas the rate of codon
translation for
each amino acid is designed to be high (optimized). However, this 'classic'
codon
optimization neglects the other codons for which tRNAs are still available.
Recently, in WO 03/85114 a harmonization of codon use was described which
takes into effect the distribution of optimal and non-optimal codons in genes,
assuming
that these effect protein folding. Using this method of harmonization of codon
use for a
gene results in the substitution of good (bad) codons in the donor organism by
good (bad)
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
2
ones in the host organism. However, this method of codon harmonization (WO
03/085114) neglects non-optimal codons since they are not replaced by more
optimal
ones. Additionally, the method cannot be applied to homologous genes.
Another publication describes an additional way to improve polypeptide
production
in a host cell by using an improved consensus translational initiator sequence
(US
6,461,837 B1); the consensus sequence 5'-nyCnnhCACC(ATG)-3' is claimed.
There is still a need for improved methods for producing a polypeptide in a
filamentous fungal cell.
Description of the Figures
Figure 1 depicts a plasmid map of expression vector pGBFIN-30. Indicated are
the glaA flanking regions relative to the glaA promoter with the unique Sfil
and EcoRl
cloning sites in the glucoamylase promoter followed by the Hindlll and Nrul
cloning sites.
The pGBFIN-30 vector is originating from pGBFIN-23 (which construction is
described in
W099/32617), with the Ascl - Xhol sites replaced by a single Nrul restriction
site. The E.
coli DNA can be removed by digestion with restriction enzyme Notl, prior to
transformation of the A. nigerstrains.
Figure 2 depicts a plasmid map of expression vector pGBFINPLA-1 a. Figure 2
also provides a representative map for plasmid pGBFINPLA 1 b and pGBFINPLA 1
c.
Indicated are the glaA flanking regions relative to the glaA promoter and the
A. oryzae
genomic plal gene encoding phospholipase Al. The E. coli DNA can be removed by
digestion with restriction enzyme Nofl, prior to transformation of the A.
nigerstrains..
Figure 3 depicts a plasmid map of expression vectors pGBFINPLA-ld through
pGBFINPLAI h. Indicated are the glaA flanking regions relative to the variant
sequences of
the glaA promoter and the A. oryzae genomic plal gene encoding phospholipase
A1. The
E. coli DNA can be removed by digestion with restriction enzyme Nofl, prior to
transformation of the A. nigerstrains.
Figure 4 depicts a plasmid map of expression vector pGBFINFUA-1. Figure 4 also
provides a representative map for plasmid pGBFINFUA-2 and pGBFINFUA-3. All
clones
originate from the pGBFIN-12 (described in W099/32617) expression vector.
Indicated
are the glaA flanking regions relative to the variant sequences of the amyA
promoter and
the A. niger amyA cDNA sequence encoding alpha-amylase. The E. coli DNA can be
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
3
removed by digestion with restriction enzyme Notl, prior to transformation of
the A. niger
strains.
Figure 5 depicts a schematic representation of integration through single
homologous recombination. The expression vector comprises the selectable amdS
marker, and the glaA promoter connected to the plal gene. These features are
flanked by
homologous regions of the glaA locus (3' glaA and 3" glaA, respectively) to
direct
integration at the genomic glaA locus.
Figure 6 depicts an alignment of the native plal coding sequence, the native
plal
genomic sequence and a synthetic optimized plal coding sequence. The introns
in the
genomic sequence are indicated in the plal genomic sequence. The codons, which
have
been changed in the modified plal coding sequence, are indicated with boxes.
The
nucleotides, which have been modified, are indicated in gray.
Figure 7 depicts phospholipase Al activity in culture broth for A. niger
strains
expressing eight different constructs (pGBFINPLA 1 a-h). Depicted is the
average
phospholipase Al activity in culture broth of A. niger strains expressing a
native
(pGBFINPLA 1 a) or modified plal constructs (pGBFINPLA-1 b-h), wherein the
translation
initiation sequence and/or the translation termination sequence and/or the
codon usage
have been modified according the method of the invention. Phospholipase
activities are
depicted in arbitrary units [AU] and are the average of at least five
independently isolated
and cultivated transformants, named as indicated (Table 6), measured after the
cultivation time as indicated.
Figure 8 depicts Phospholipase Al activity in culture broth for A. niger
strains
expressing three different constructs. Depicted is the phospholipase Al
activity in culture
broth of three A. niger strains expressing a native (pGBFINPLA-1 a) or
modified plal
construct, wherein the translation initiation sequence and the translation
termination
sequence (pGBFINPLA 1 b) and the translation initiation sequence, the
translation
termination sequence and the codon usage (pGBFINPLA 1 e) were modified
according a
method of the invention. Phospholipase activities are depicted in arbitrary
units [AU] for 2-
copy plal transformants, named as indicated (Table 6), and measured after the
cultivation time indicated.
Figure 9 depicts Alpha-amylase activity in culture broth for A. niger strains
expressing three different constructs. Depicted is the alpha-amylase activity
in culture
broth of A. nigerstrains expressing a native (pGBFINFUA-1) or modified
amyAconstruct,
wherein the translation initiation sequence and the translation termination
sequence were
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
4
modified (pGBFINFUA-2) and the translation initiation sequence, the
translation
termination sequence and the codon usage were modified (pGBFINFUA-3) according
a
method of the invention. Alpha-amylase activities are depicted in relative
units [AU], with
the average of the 7 one-copy strains of the FUA1 group of 10 strains at day 4
set at
100%. The ten transformants per group indicated are independently isolated and
cultivated transformants, named as indicated in Table 9, and measured the the
cultivation
time as indicated.
Detailed description of the invention
A new approach to improve production of a compound of interest in a
filamentous
fungal cell is proposed based on modification of the protein encoding or
coding sequence
and optionally the associated 'non-coding' or control sequences that might
have impact
on translation efficiency and/or efficiency of production of the compound of
interest.
Nucleotide sequences
According to a first aspect of the invention, there is provided a nucleotide
sequence comprising:
- a synonymous nucleotide coding sequence with optimized codon
frequency such that a native codon has been exchanged with a synonymous codon,
said
synonymous codon encoding the same amino acid as the native codon and having a
higher frequency in codon usage as defined in Table 1 than the native codon;
and
optionally said nucleotide sequence comprising control sequences such as:
- one translational termination sequence orientated in 5' towards 3' direction
selected from the following list of sequences: TAAG, TAGA and TAAA, preferably
TAAA,
and/or
- one translational initiator coding sequence orientated in 5' towards 3'
direction selected from the following list of sequences: GCTACCCCC; GCTACCTCC;
GCTACCCTC; GCTACCTTC; GCTCCCCCC; GCTCCCTCC; GCTCCCCTC;
GCTCCCTTC; GCTGCCCCC; GCTGCCTCC; GCTGCCCTC; GCTGCCTTC;
GCTTCCCCC; GCTTCCTCC; GCTTCCCTC; and GCTTCCTTC, preferably GCT TCC
TTC.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
Table 1: Optimal filamentous fungal codon frequency for synonymous codons in %
.T. C. A. G.
Phe Ser Tyr Cys
T.. 0 21 0 0 T
Phe Ser Tyr Cys
T.. 100 44 100 100 . C
Leu Ser Stop Stop
T.. 0 0 100 0 A
Leu Ser Stop Trp
T.. 13 14 0 100 ..G
Leu Pro His Arg
C.. 17 36 0 49 ..T
Leu Pro His Arg
C.. 38 64 100 51 . C
Leu Pro Gln Arg
C.. 0 0 0 0 ..A
Leu Pro Gln Arg
C.. 32 0 100 0 .. G
Ile Thr Asn Ser
A.. 27 30 0 0 .. T
Ile Thr Asn Ser
A.. 73 70 100 21 .. C
Ile Thr Lys Arg
A.. 0 0 0 0 ..A
Met Thr Lys Arg
A.. 100 0 100 0 .. G
Val Ala Asp Gly
G.. 27 38 36 49 .. T
Val Ala Asp Gly
G.. 54 51 64 35 C
G.. Val Ala Glu Gly .. A
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
6
0 0 26 16
Val Ala Glu Gly
G.. 19 11 74 0 G
According to a preferred embodiment, said nucleotide sequence is a sequence
wherein the optimized codon frequency of said synonymous nucleotide coding
sequence
comprised in said nucleotide sequence is such that at least one native codon,
preferably
at least two native codons, more preferably at least three native codons, more
preferably
at least four native codons, more preferably at least five native codons, more
preferably at
least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 50%, 75%, 80%, 85%, 90%, and
most
preferably at least 95% of the native codons have been exchanged with a
synonymous
codon, said synonymous codon encoding the same amino acid as the native codon
and
having a higher frequency in codon usage as defined in Table 1 than the native
codon.
According to a more preferred embodiment, said nucleotide sequence is a
sequence wherein the optimized codon frequency of said synonymous nucleotide
coding
sequence comprised in said nucleotide sequence is such that at least one
native codon,
preferably at least two native codons, more preferably at least three native
codons, more
preferably at least four native codons, more preferably at least five native
codons, more
preferably at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 50%, 75%, 80%,
85%,
90%, and most preferably at least 95% of the native codons have been exchanged
with a
synonymous codon, the synonymous codon changing the codon frequency such that
the
value of the absolute difference between the percentage for said synonymous
codon in
said frequency and the listed optimal percentage becomes smaller after
modification,
applying the following list of optimal percentages: cysteine by TGC (100%);
phenylalanine
by TTC (100%); histidine by CAC (100%); lysine by AAG (100%); asparagine by
AAC
(100%); glutamine by CAG (100%); tyrosine by TAC (100%); alanine is encoded by
GCT
(38%), GCC (51 %), or GCG (11 %); aspartate by GAC (64%); glutamate by GAG
(74%);
glycine by GGT (49%), GGC (35%), GGA (16%); isoleucine by ATT (27%), ATC
(73%);
leucine by TTG (13%), CTT (17%), CTC (38%), CTG (32%); proline by CCT (36%),
CCC
(64%); arginine by CGT (49%), CGC (51%); serine by TCT (21%), TCC (44%), TCG
(14%), AGC (21%); threonine by ACT (30%), ACC (70%) and/or valine by GTT
(27%),
GTC (54%), GTG (19%).
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
7
According to an even more preferred embodiment, said nucleotide sequence is a
sequence wherein the codon fitness of said synonymous nucleotide coding
sequence
with optimized codon frequency comprised in said nucleotide sequence has a
fitness
value that is at least 70%, 80%, 90%, 95%, preferably 96%, 97%, 98%, and most
preferable >98%, where the codon fitness is the calculated by means of the
following
function:
.fit (g) =100- 1 . I~y r~g
c er (c(k)) - r g (c(k))i 100
~g~ k=1
where g symbolizes a nucleotide coding sequence, DI its length, g(k) its k-th
codon, r~ arget (c(k)) is a desired ratio of codon c(k) and rg (c(k)) an
actual ratio in the
nucleotide coding sequence g.
In the context of the invention, both nucleotide coding sequence and control
sequence are herein named native or wild type when one refers to these
sequences
before the method of the invention has been applied to. Once having been
modified by the
invention, they would be named modified or synonymous sequences. Consequently,
synonymous sequences would generally te recognized as recombinant sequences.
Incidentally, a sequence occurring in nature may be identical to the
synonymous
sequence.
In the context of the invention, a nucleotide coding sequence and a synonymous
nucleotide coding sequence may directly encode a compound of interest to be
produced.
The term compound of interest is defined later in the section "Production of a
compound
of interest". An example of a compound of interest that is directly encoded by
a
(synonymous) nucleotide coding sequence is a polypeptide, preferably, the
polypeptide is
an enzyme, more preferably an enzyme that is secreted outside the cell.
Alternatively, the
compound encoded by the (synonymous) nucleotide coding sequence may not be the
compound of interest per se, but may inter alia be involved in the production
of the
compound of interest. In this case, the compound encoded by the (synonymous)
nucleotide coding sequence can be, but is not limited to, an intracellular
enzyme involved
in the production of a metabolite, a transporter, a transcription factor, a
structural protein,
a chaperone or the product of a housekeeping gene.
In the context of the invention the term "codon" generally refers to a
nucleotide
triplet, which codes for an amino acid. As used herein "synonymous codon"
refers to a
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
8
codon which does not have the identical nucleotide sequence, but which encodes
the
identical amino acid (AA). The term "codon frequency", "codon bias", or "codon
usage" is
defined as the frequency at which the different corresponding codons are used
in a
coding sequence. Codon usage is based on the fact that several codons in a
coding
sequence encode the same amino acid, but that the frequency of the different
codons
encoding said amino acid may vary between various coding sequences.
A nucleotide coding sequence (encoding a polypeptide) that is homologous or
heterologous to the host cell used for production may originate for example
from a virus,
a prokaryote, a fungus, a filamentous fungus, other eukaryotes and higher
eukaryotes,
like mammals, human and plants. This (native) nucleotide coding sequence is
modified
according to the optimal codon frequency as described in Table 1 (and further
disclosed
in paragraph "Calculation of "optimized codon frequency" or "optimized codon
usage"
using Table 1"), generating a synonymous nucleotide sequence. The native,
coding
sequence may be selected from the group of:
- a wild-type nucleotide sequence coding for a predetermined amino acid
sequence,
- a back-translation of a natural occurring amino acid sequence using random
choice for the codons,
- a non-naturally occurring amino acid sequence, displaying homology to a
known
amino acid sequence, e.g. a shuffled sequence,
- part of the sequences mentioned her above, e.g. to be used in fusion
sequences.
The synonymous nucleotide coding sequence with optimized codon usage, is
preferably expressed in an Aspergillus, Trichoderma, Fusarium, Chrysosporum or
Penicillium host cell. More preferably the synonymous nucleotide coding
sequence is
expressed in an Aspergillus niger, Aspergillus oryzae, Aspergillus sojae,
Aspergillus
terreus, Trichoderma reesei, Chrysosporum lucknowense or Penicillium
chrysogenum
host cell. A most preferred Aspergillus niger host cell is CBS513.88 or
derivatives
thereof. Preferably, the expression of the product encoded by the synonymous
coding
sequence present is enhanced as compared to the production of the
corresponding
native coding sequence, said corresponding nucleic acid construct being
present in the
same copy number in a corresponding filamentous fungal host cell. Preferably,
the
modification of the nucleotide coding sequence, (resulting in a synonymous
nucleotide
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
9
coding sequence of the invention) results in an increase of at least 1%, 5%,
10%, 25%,
50%, 100%, 200%, 300%, 400% more preferably at least 500% of the yield of the
compound of interest produced by the filamentous fungal host cell of the
invention
comprising a given copy number of the synonymous nucleotide coding sequence,
as
compared to the production of the native nucleotide coding sequences being
present in
the same copy number in a corresponding filamentous fungal host cell.
The increase in yield of the compound of interest to be produced may be
determined by measuring the amount of compound produced by the filamentous
fungal
host cell of the invention and comparing it to the compound of interest
produced by the
corresponding filamentous fungal host cell. Determining the yield of compound
of interest
produced may be performed by measuring inter alia the amount of mRNA
transcribed
from the (synonymous) nucleotide coding sequence, the amount of polypeptide
encoded
by the mRNA, or the amount of compound (e.g. metabolite) in which' production
the
polypeptide encoded by the synonymous nucleotide coding sequence is involved
with.
Examples of methods known to the skilled person to determine the amount of
mRNA
include, but are not limited to Northern blot, Quantitative PCR, Real Time
PCR, and
micro-array analyses. The amount of polypeptide can inter alia be determined
using
protein measurement assays known to the skilled person. When the polypeptide
is an
enzyme, the amount of polypeptide can be measured using an activity assay
specific for
the concerned enzyme. The skilled person will know which assay to select for a
specific
enzyme. A preferred assay to determine the yield of the compound of interest
to be
produced is an activity assay specific for the concerned enzyme.
Considering the optimal codon usage as defined in Table 1 and codon bias
between the genes of an organism, a native coding nucleotide sequence encoding
a
homologous polypeptide may also be considered subject to codon optimization
and
provide a higher yield for the homologous polypeptide than would the
expression of the
native nucleotide sequence in the same host.
In the context of this invention, a nucleotide coding sequence or coding
sequence
is defined as a nucleotide sequence encoding a polypeptide. The boundaries of
the
nucleotide coding sequence are generally determined by the ATG start codon
located at
the beginning of the open reading frame at the 5' end of the mRNA and a stop
codon
located just downstream of the open reading frame at the 3' end of the mRNA. A
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
nucleotide coding sequence can include, but is not limited to, DNA, cDNA, RNA,
and
recombinant nucleic acid (DNA, cDNA, RNA) sequences. If the coding sequence is
intended for expression in a eukaryotic cell, a polyadenylation signal and
transcription
termination sequence will usually be located 3' to the coding sequence. A
nucleotide
5 coding sequence comprises a translational initiator coding sequence, and
optionally a
signal sequence.
In order to attain expression of the nucleotide coding sequence, the
nucleotide
coding sequence is preferably combined with a control sequence. In the context
of the
10 invention, a control sequence is defined as a nucleotide sequence necessary
or
advantageous for expression of the nucleotide sequence encoding a polypeptide.
When
present together, the control sequence is operatively associated to the
nucleotide coding
sequence. The term "control sequence" includes all genetic elements necessary
or
advantageous for expression of a nucleotide coding sequence. Each control
sequence
may be native or foreign to the nucleotide coding sequence. Control sequences
include,
but are not limited to, a leader sequence, a polyadenylation sequence, a
propeptide
sequence, a promoter, a translational initiator sequence, a translational
initiator coding
sequence, a translational transcription terminator and a transcription
terminator
sequence. The control sequences may be provided with linkers, e.g., for the
purpose of
introducing specific restriction sites facilitating ligation of the control
sequences with the
coding region of the nucleotide sequence encoding a polypeptide.
The term "operatively associated" is defined herein as a configuration in
which a
control sequence is appropriately placed at a position relative to a
(synonymous)
nucleotide coding sequence such that the control sequence directs the
expression of the
(synonymous) nucleotide coding sequence.
In the context of this invention, the term "translational initiator coding
sequence" is
defined as the nine nucleotides immediately downstream of the initiator or
start codon of
the open reading frame of a DNA coding sequence. The initiator or start codon
encodes
for the AA methionine. The initiator codon is typically ATG, but may also be
any functional
start codon such as GTG. The term "consensus translational initiator coding
sequence"
is defined herein as the nine nucleotides immediately downstream of the
initiator codon of
the open reading frame of a DNA coding sequence and having the following DNA
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
11
sequence: 5'-GCTnCCyyC-3' (i.e. SEQ ID NO. 20), using ambiguity codes for
nucleotides y(C/T) and n(A/C/G/T). This leads to 16 variants for the
translational initiator
coding sequence: GCTACCCCC; GCTACCTCC; GCTACCCTC; GCTACCTTC;
GCTCCCCCC; GCTCCCTCC; GCTCCCCTC; GCTCCCTTC; GCTGCCCCC;
GCTGCCTCC; GCTGCCCTC; GCTGCCTTC; GCTTCCCCC; GCTTCCTCC;
GCTTCCCTC; GCTTCCTTC. Preferably, the translational initiator coding sequence
has
the nucleic acid sequence: 5'- GCT TCC TTC -3' (i.e. SEQ ID NO. 21).
Using a consensus translational initiator coding sequence, the following AA
are
allowed at the AA positions mentioned: alanine at +2, alanine, serine,
proline, or threonine
at +3, and phenylalanine, serine, leucine or proline at +4 position in the
polypeptide that is
encoded. In the present invention, the consensus translational initiator
coding sequence
may be foreign to the nucleic acid sequence encoding the polypeptide to be
produced.
Alternatively, the consensus translational initiator may be native to the
fungal host cell.
In the context of this invention, the term "translational termination
sequence" is
defined as the four nucleotides starting from the translational stop codon at
the 3' end of
the open reading frame or nucleotide coding sequence and oriented in 5'
towards 3'
direction. Preferably, the translational termination sequence is selected from
the following
list of sequences: 5'-TAAG-3', 5'- TAGA-3' and 5'-TAAA-3'. More preferably,
the
translational termination sequence is: 5'-TAAA-3'.
The term "optimized codon frequency" or "optimized codon usage" as used
herein refers to a native nucleotide coding sequence, which has been modified
wholly or
partly to give a synonymous nucleotide coding sequence according to the codon
usage
as described in Table 1 (and further disclosed in paragraph "Calculation of
"optimized
codon frequency" or "optimized codon usage" using Table 1"). Optimizing codon
frequency can be used to improve any coding sequence for any given polypeptide
to be
produced in any filamentous fungal species as host cell. Preferably, the
filamentous
fungal host cell is an Aspergillus, Trichoderma, Fusarium, Chrysosporum or
Penicillium
host cell. More preferably the filamentous fungal host cell is an Aspergillus
niger,
Aspergillus oryzae, Aspergillus sojae, Aspergillus terreus, Trichoderma
reesei,
Chrysosporum lucknowense or Penicillium chrysogenum host cell. A most
preferred
Aspergillus niger host cell is CBS513.88 or derivatives thereof. A more
exhaustive list of
the preferred host cells is given under the section "Host cells".
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
12
When the amino acid sequence of a polypeptide sequence has been determined,
a nucleotide sequence encoding the polypeptide with optimized codon frequency
for
expression in the host cell or synonymous nucleotide coding sequence can be
synthesized in which one or more of the native codons have been exchanged with
a
synonymous codon encoding the same amino acid, said synonymous codon having a
higher frequency in the codon usage as defined in Table 1 (and further
disclosed in
paragraph "Method for producing a nucleotide sequence; calculation of the
optimized
codon frequency" using Table 1").
A nucleotide sequence encoding a polypeptide or synonymous coding sequence
is considered to have an optimized codon frequency when at least one native
codon, at
least two native codons, at least three native codons, at least four native
codons, at least
five native codons or at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 50%,
75%,
80%, 85%, 90%, or preferably at least 95% of the native codons have been
exchanged
with a synonymous codon, the synonymous codon encoding the same amino acid as
the
native codon and having a higher frequency in the codon usage as defined in
Table 1 than
the native codon.
A nucleotide sequence encoding a polypeptide or synonymous coding sequence
is considered to have an optimized codon frequency when at least one native
codon, at
least two native codons, at least three native codons, at least four native
codons, at least
five native codons or at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 50%,
75%,
80%, 85%, 90%, or preferably at least 95% of the native codons have been
exchanged
with a synonymous codon, the synonymous codon changing the codon frequency
such
that the value of the absolute difference between the percentage for said
codon in said
frequency and listed optimal percentage becomes smaller after modification,
applying the
following list of optimal percentages: cysteine by TGC (100%); phenylalanine
by TTC
(100%); histidine by CAC (100%); lysine by AAG (100%); asparagine by AAC
(100%);
glutamine by CAG (100%); tyrosine by TAC (100%); alanine is encoded by GCT
(38%) ,
GCC (51 %), or GCG (11 %); aspartate by GAC (64%); glutamate by GAG (74%);
glycine
by GGT (49%), GGC (35%), GGA (16%); isoleucine by ATT (27%), ATC (73%);
leucine
by TTG (13%), CTT (17%), CTC (38%), CTG (32%); proline by CCT (36%), CCC
(64%);
arginine by CGT (49%), CGC (51%); serine by TCT (21%), TCC (44%), TCG (14%),
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
13
AGC (21%); threonine by ACT (30%), ACC (70%) and/or valine by GTT (27%), GTC
(54%), GTG (19%).
Codon fitness is defined to be the difference of the actual codon ratios in
the gene
and the target codon ratios, normalized for the number of occurrences of every
codon.
Let r'a'ge'(c(k)) be the desired ratio (or frequency) of codon ck and rg
(c(k)) as before
sc sc
the actual ratio in the gene g, then the single codon fitness is defined as:
.fitc(g)=100- 1 . Irrarg er(c(k))-r9(c(k))~=100
~g~ k=1
Thus, codon fitness #itc(g)} can reach values between 0 and 100% with the
optimal sequence being close to 100%. Consequently, a synonymous nucleotide
coding
sequence is considered to have an optimized codon frequency when the codon
fitness
value of the synonymous coding sequence is at least 70%, 80%, 90%, 95%,
preferably
96%, 97%, 98%, and most preferable >98%.
The nucleotide sequence of the invention may be a synthetic nucleotide
sequence. As used herein, the term "synthetic" gene, DNA construct, nucleic
acid,
polynucleotide, primer, or the like means a nucleotide sequence that is not
found in
nature; in other words, not merely a heterologous sequence to a particular
organism, but
one which is heterologous in the sense that it has been designed and/or
created in a
laboratory, and has been altered in some way that it does not have an
identical nucleotide
(or possibly AA) sequence to the one of its naturally occurring source,
template or
homologue. A synthetic nucleic acid or AA sequence as used herein can refer to
a
theoretical sequence or a tangibly, physically created embodiment. It is
intended that
synthetic sequences according to the invention are included in the invention
in any form,
e.g. paper or computer readable and physically created nucleic acid sequences,
proteins,
peptides, fused peptides or multi-peptides.
Alternative, a naturally occurring nucleotide sequence may display the
features of
the invention. The use of such sequence is considered to be encompassed within
the
invention.
The term 'synthetic nucleotide construct" or "synthetic nucielc acid" can
inciude
nucieic aclds derived or designed from wholly artificlal amino acid sequences
or nucleic
acid sequences with singie or rrsultipie nucleotide changes compared to the
naturaily
occurring sequence. These "synthetic DNA constructs" can be created by random
or
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
14
directed mutagenesis; DNA shuffling methods, DNA reassembly methods, gene
synthesis, or by any means known to one skilled in the art (see for example
Young and
Dong, (2004), Nucleic Acids Research 32; (7) electronic access
http.//nar.ouglournals.orgr'cgi/regrintf3217re59 or Gupta ef al. (1968), Proc.
Natl. Acad. Sci
USA, 60: 1338-1344; Scarpulla ef ad. (1982), Anal. Biocherrs. 121: 356m365;
Stemmer et
al. (1995), Gene 164: 49653).
Alternatively, a synthetic nucleotide sequence may be designed from an amino
acid sequence (see example 2). Using this reverse engineering method there is
no need
for a naturally occurring nucleotide sequence, which may not be available. A
back-
translation may first be performed using random choice for the codonse
Subsequently;
the resulting nucleotide sequence can be optimized for codon usage.
According to another preferred embodiment, a synonymous nucleotide coding
sequence with optimized codon frequency according to the invention is a
reverse
engineered nucleotide coding sequence, wherein the optimized codon frequency
is such
that at least one codon, at least two codons, at least three codons, at least
four codons,
at least five codons or at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 2M 25%, 50%,
75%,
80%, 85%, 90%, or preferably at least 95% of the codons have a higher
frequency In the
codon usage as defined in Table 1 than the codon usage that is predicted by
the
arithmetic average (i.e., 100% in case of 1 codon, 50% in case of two codons,
33 0% in
case of 3 codons, 25% in case of 4 codons, and 16e7% in case of 6 codons).
According to a more preferred embodiment, said synonymous nucleotide
coding sequence with optimized codon frequency is a reverse engineered
nucleotide
coding sequence wherein the codon fitness of the nucleotide coding sequence
has a
fitness value that is at least 70%, 80%, 90%, 95%, preferably 96%, 97%, 98%,
and most
preferable >98%, where the codon fitness is the calculated by means of the
following
function:
fit(g)=100- 1 . I~y.r~g
c er(c(k))-rg(c(k))l 100
~g~ k=1
where g symbolizes a nucleotide coding sequence, DI its length, g(k) its k-th
codon, Y~ ~get (c(k)) is a desired ratio of codon c(k) and rg (c(k)) a
calculated ratio in the
nucleotide coding sequence g.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
In addition to the control sequences that may be present in the nucleotide
sequence of the invention, the nucleotide coding sequence may comprise a
signal
sequence, or signal peptide-coding region.
A signal sequence codes for an amino acid sequence linked to the amino
5 terminus of the polypeptide, which can direct the expressed polypeptide into
the cell's
secretory pathway. The 5'-end of the coding sequence of the nucleotide
sequence may
inherently contain a signal peptide-coding region naturally linked in
translation reading
frame with the segment of the coding region that encodes the secreted
polypeptide of
interest. In that case, the translational initiator coding sequence is part of
the signal
10 sequence. Alternatively, the 5'-end of the coding sequence may contain a
signal peptide-
coding region, which is foreign to that portion of the coding sequence that
encodes the
secreted protein. A foreign signal peptide-coding region may be required where
the
coding sequence does not normally contain a signal peptide-coding region.
Alternatively,
a foreign signal peptide-coding region may simply replace the natural signal
peptide-
15 coding region in order to obtain enhanced secretion of the protein (s)
relative to the
natural signal peptide-coding region normally associated with the coding
sequence. The
signal peptide-coding region may be obtained from a glucoamylase or an amylase
gene
from an Aspergillus species, a lipase or proteinase gene from a
Rhizomucorspecies, the
gene for the alpha-factor from Saccharomyces cerevisiae, an amylase or a
protease
gene from a Bacillus species, or the calf preprochymosin gene. However, any
signal
peptide-coding region capable of directing the expressed protein into the
secretory
pathway of a host cell of choice may be used in the present invention.
Preferred signal
peptide coding regions for filamentous fungus host cells are the signal
peptide coding
region obtained from Aspergillus oryzae TAKA amylase gene (EP 238 023),
Aspergillus
niger neutral amylase gene, Aspergillus niger glucoamylase, the Rhizomucor
miehei
aspartic proteinase gene, the Humicola lanuginosa cellulase gene, Humicola
insolens
cellulase, Humicola insolens cutinase, the Candida antactica lipase B gene or
the
Rhizomucor miehei lipase gene and mutant, truncated, and hybrid signal
sequence
thereof.
In another preferred embodiment, the synonymous nucleotide coding sequence
with optimized coding frequency of the invention comprises a signal sequence.
According
to a more preferred embodiment, the signal sequence of the invention is a
signal
sequence with an optimized codon frequency where at least one native codon, or
at least
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
16
1%, 5%, 10%, 25%, 50%, 75%, 80%, 85%, 90%, or preferably at least 95% of the
native
codons have been exchanged with a synonymous codon, said synonymous codon
encoding the same amino acid as the native codon and having a higher frequency
in
codon usage than the native codon as defined in Table 1 and further disclosed
in
paragraph "Calculation of "optimized codon frequency" or "optimized codon
usage" using
Table 1". More preferably, the signal sequence of the invention comprises a
translational
initiator coding sequence having the following consensus DNA sequence: 5'-
GCTnCCyyC-0' (i.e. SEQ ID NO. 20) or even more preferably a translational
initiator
coding sequence with the nucleic acid sequence: 5'- GCT TCC TTC -8' (i,e. SEQ
ID NO.
21).
The nucleotide coding sequence may, before a modification of the invention is
applied, contain one or more introns that contain nucleotides that are not
encoding amino
acids in the protein sequence. One of the steps in optimizing the expression
of the coding
sequence might be to use the synonymous coding sequence without introns. In
example
2, the introns present in the native nucleotide sequence were not replaced in
the modified
constructs.
Alternatively, and according to another preferred embodiment of the invention,
in a
nucleotide sequence comprising a synonymous nucleotide coding sequence of the
invention wherein the unmodified nucleotide coding sequence originally
comprised one or
more introns, at least one intron has been re-introduced in the nucleotide
coding
sequence, preferably, but not necessarily, at the original position. In
example 1, the
introns that are part of the A. oryzae plal DNA sequence were replaced in the
codon-
optimized (synonymous) DNA sequence, which was used for expression.
Translational initiator seguences
In a second aspect, the invention relates to translational initiator
sequences. A
translational initiator sequence is the nucleic acid region encoding a protein
start and the
biological activity of a translational initiator sequence is to initiate the
ribosome-mediated
production of a polypeptide whose amino acid sequence is specified by the
nucleotide
sequence in an mRNA. In eukaryotes, the translational initiator consensus
sequence (6-
12 nucleotides) before the ATG is often called Kozak consensus sequence due to
the
initial work on this topic (Kozak, M. (1987): an analysis of 5'-noncoding
sequences from
699 vertebrate messenger RNAs. Nucl. Acid Res. 15(20): 8125-47). The original
Kozak
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
17
consensus sequence CCCGCCGCCrCC(ATG)G, including a +4 nucleotide derived by
Kozak is associated with the initiation of translation in higher eukaryotes.
In the context of
this invention, the term "translational initiator sequence" is defined as the
ten nucleotides
immediately upstream of the initiator or start codon of the open reading frame
of a DNA
sequence coding for a polypeptide. The initiator or start codon encodes for
the AA
methionine. The initiator codon is typically ATG, but may also be any
functional start
codon such as GTG. It is well known in the art that uracil, U, replaces the
deoxynucleotide
thymine, T, in RNA.
The biological activity of a transcriptional initiator sequence can be
determined in
a quantitative way by measuring the amount of transcribed gene-product of the
open
reading frame immediately downstream of the transcriptional initiator sequence
and
comparing this amount to the amount measured from the same open reading frame
controlled by a reference transcriptional initiator sequence. The amount of
gene product
may be determined by measuring either the amount of mRNA or the amount of
polypeptide encoded by the mRNA. Examples of methods known to the skilled
person to
determine the amount of mRNA include, but are not limited to Northern blot,
Quantitative
PCR, Real Time PCR, and micro-array analyses. The amount of polypeptide
encoded by
the open reading frame immediately downstream of the transcriptional initiator
sequence
can inter alia be determined using protein measurement assays known to the
skilled
person. When the polypeptide encoded by the open reading frame immediately
downstream of the transcriptional initiator sequence is an enzyme, the amount
of
polypeptide can be measured using an activity assay specific for the concerned
enzyme.
The skilled person will know which assay to select for a specific enzyme. A
preferred
assay to determine the biological activity of the transcriptional initiator
sequence is an
activity assay specific for a concerned enzyme.
According to a preferred embodiment, a nucleotide sequence, preferably a
nucleotide sequence of the first aspect of the invention, comprises a
translational initiator
sequence, said translational initiator sequence comprises the nucleic acid
sequence as
defined by the consensus translational initiator sequence: 5'-mwChkyCAmv-3'
(i.e. SEQ
ID NO. 16), using ambiguity codes for nucleotides: m(A/C); r(A/G); w(A/T);
s(C/G); y
(C/T); k(G/T); v(A/C/G); h(A/C/T); d(A/G/T); b(C/G/T); n(A/C/G/T). More
preferably, the
consensus translational initiator sequence is one selected from the following
list: 5'-
mwChkyCAAA-3' (i.e. SEQ ID NO. 17); 5'-mwChkyCACA-3' (i.e. SEQ ID NO. 18) or
5'-
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
18
mwChkyCAAG-3' (i.e. SEQ ID NO. 19). These more preferred sequences correspond
to
any one of the following sequences: AACAGCCAAA; AACAGTCAAA; AACATCCAAA;
AACATTCAAA; AACCGCCAAA; AACCGTCAAA; AACCTCCAAA; AACCTTCAAA;
AACTGCCAAA; AACTGTCAAA; AACTTCCAAA; AACTTTCAAA; ATCAGCCAAA;
ATCAGTCAAA; ATCATCCAAA; ATCATTCAAA; ATCCGCCAAA; ATCCGTCAAA;
ATCCTCCAAA; ATCCTTCAAA; ATCTGCCAAA; ATCTGTCAAA; ATCTTCCAAA;
ATCTTTCAAA; CACAGCCAAA; CACAGTCAAA; CACATCCAAA; CACATTCAAA;
CACCGCCAAA; CACCGTCAAA; CACCTCCAAA; CACCTTCAAA; CACTGCCAAA;
CACTGTCAAA; CACTTCCAAA; CACTTTCAAA; CTCAGCCAAA; CTCAGTCAAA;
CTCATCCAAA; CTCATTCAAA; CTCCGCCAAA; CTCCGTCAAA; CTCCTCCAAA;
CTCCTTCAAA; CTCTGCCAAA; CTCTGTCAAA; CTCTTCCAAA; CTCTTTCAAA;
AACAGCCACA; AACAGTCACA; AACATCCACA; AACATTCACA; AACCGCCACA;
AACCGTCACA; AACCTCCACA; AACCTTCACA; AACTGCCACA; AACTGTCACA;
AACTTCCACA; AACTTTCACA; ATCAGCCACA; ATCAGTCACA; ATCATCCACA;
ATCATTCACA; ATCCGCCACA; ATCCGTCACA; ATCCTCCACA; ATCCTTCACA;
ATCTGCCACA; ATCTGTCACA; ATCTTCCACA; ATCTTTCACA; CACAGCCACA;
CACAGTCACA; CACATCCACA; CACATTCACA; CACCGCCACA; CACCGTCACA;
CACCTCCACA; CACCTTCACA; CACTGCCACA; CACTGTCACA; CACTTCCACA;
CACTTTCACA; CTCAGCCACA; CTCAGTCACA; CTCATCCACA; CTCATTCACA;
CTCCGCCACA; CTCCGTCACA; CTCCTCCACA; CTCCTTCACA; CTCTGCCACA;
CTCTGTCACA; CTCTTCCACA; CTCTTTCACA; AACAGCCAAG; AACAGTCAAG;
AACATCCAAG; AACATTCAAG; AACCGCCAAG; AACCGTCAAG; AACCTCCAAG;
AACCTTCAAG; AACTGCCAAG; AACTGTCAAG; AACTTCCAAG; AACTTTCAAG;
ATCAGCCAAG; ATCAGTCAAG; ATCATCCAAG; ATCATTCAAG; ATCCGCCAAG;
ATCCGTCAAG; ATCCTCCAAG; ATCCTTCAAG; ATCTGCCAAG; ATCTGTCAAG;
ATCTTCCAAG; ATCTTTCAAG; CACAGCCAAG; CACAGTCAAG; CACATCCAAG;
CACATTCAAG; CACCGCCAAG; CACCGTCAAG; CACCTCCAAG; CACCTTCAAG;
CACTGCCAAG; CACTGTCAAG; CACTTCCAAG; CACTTTCAAG; CTCAGCCAAG;
CTCAGTCAAG; CTCATCCAAG; CTCATTCAAG; CTCCGCCAAG; CTCCGTCAAG;
CTCCTCCAAG; CTCCTTCAAG; CTCTGCCAAG; CTCTGTCAAG; CTCTTCCAAG or
CTCTTTCAAG.
According to a more preferred embodiment, the translational initiatior
sequence is
5'-CACCGTCAAA-3' (i.e. SEQ ID NO. 22) or 5'-CGCAGTCAAG-3' (i.e. SEQ ID NO.
23).
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
19
The present invention further encompasses isolated translational initiator
sequences, variants and subsequences thereof still having the same biological
activity as
the isolated translational initiator sequence.
The consensus translational initiator sequence of the invention is preferably
comprised in a nucleotide sequence of the first aspect of the invention.
Alternatively, the
consensus translational initiator sequence of the invention may be comprised
in any
nucleotide sequence comprising a nucleotide coding sequence encoding a
compound of
interest. The nucleotide coding sequence may be any coding sequence.
Preferably, the
nucleotide coding sequence is a synonymous coding sequence as defined
previously.
Furthermore, and according to another aspect of the invention, there is
provided a
nucleic acid construct or expression vector as defined in the section "Nucleic
acid
constructs", said nucleic acid construct or expression vector comprising the
consensus
translational initiator sequence of the invention.
The consensus translational initiator sequence of the invention can be used in
any
filamentous fungal cell for expressing any nucleic acid sequence encoding any
compound to be produced in said cell. Filamentous fungal cells are defined in
the section
"Host cells".
In the present invention, the consensus translational initiator sequence is
preferably foreign to the nucleic acid sequence encoding the polypeptide to be
produced,
but the consensus translational initiator sequence may be native to the fungal
host cell.
The skilled person will understand that the invention relates to several
distinct
embodiments, which can be used separately or in combination:
- a synonymous nucleotide coding sequence by using optimal codon
frequency and/or modification of control sequences such as:
- a translational termination sequence orientated in 5' towards 3' direction
selected from the list of sequences: TAAG, TAGA and TAAA, preferably TAAA,
and/or
- a translational initiator coding sequence orientated in 5' towards 3'
direction selected from the list of sequences: GCTACCCCC; GCTACCTCC;
GCTACCCTC; GCTACCTTC; GCTCCCCCC; GCTCCCTCC; GCTCCCCTC;
GCTCCCTTC; GCTGCCCCC; GCTGCCTCC; GCTGCCCTC; GCTGCCTTC;
GCTTCCCCC; GCTTCCTCC; GCTTCCCTC; and GCTTCCTTC, preferably GCT TCC
TTC, and/or
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
- a translational initiator sequence, said translational initiator sequence
comprising the nucleic acid sequence as defined by the consensus translational
initiator
sequence: 5'-mwChkyCAmv-3', using ambiguity codes for nucleotides: m (A/C); r
(A/G);
w(A/T); s(C/G); y (C/T); k (G/T); v(A/C/G); h(A/C/T); d(A/G/T); b (C/G/T);
n(A/C/G/T),
5 preferably the translational initiator sequence is one selected from the
following list: 5'-
mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3', more preferably, the
translational initiator sequence is 5'-CACCGTCAAA-3' or 5'-CGCAGTCAAG-3'.
The skilled person will understand that the invention relates to several
distinct
10 embodiments, which can be used separately or in various distinct
combinations, several
of these combinations are disclosed below.
Preferably, the nucleotide sequence of the invention comprises a synonymous
coding sequence, which has an optimized codon frequency according the
invention as
disclosed herein.
According to a more preferred embodiment, the nucleotide sequence of the
invention comprises a synonymous coding sequence, which has an optimized codon
frequency according the invention as disclosed herein, said synonymous coding
sequence being associated with a control sequence comprising one translational
termination sequence orientated in 5' towards 3' direction selected from the
following list:
5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. More preferably, the nucleotide
sequence of the
invention comprises a synonymous coding sequence, which has an optimized codon
frequency according the invention as disclosed herein, said synonymous coding
sequence being associated with a control sequence comprising the following
translational termination sequence 5'-TAAA-3'.
According to an even more preferred embodiment, the nucleotide sequence of the
invention comprises a synonymous coding sequence, which has an optimized codon
frequency according the invention as disclosed herein, said synonymous coding
sequence being associated with a control sequence comprising one translational
initiator
sequence selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3',
and
5'-mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier
disclosed).
More preferably, the nucleotide sequence comprises a synonymous coding
sequence,
which has an optimized codon frequency according the invention as disclosed
herein,
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
21
said synonymous coding sequence being associated with a control sequence
comprising
one translational initiator sequence selected from the following list: 5'-
CACCGTCAAA-3'
and 5'-CGCAGTCAAG-3'. Even more preferably, the nucleotide sequence comprises
a
synonymous coding sequence, which has an optimized codon frequency according
the
invention as disclosed herein, said synonymous coding sequence being
associated with
the following translational initiator sequence 5'-CGCAGTCAAG-3'. Most
preferably, the
nucleotide sequence comprises a synonymous coding sequence, which has an
optimized codon frequency according the invention as disclosed herein, said
synonymous coding sequence being associated with the following translational
initiator
sequence 5'-CACCGTCAAA-3'.
According to a yet even more preferred embodiment, the nucleotide sequence
comprises a synonymous coding sequence, which has an optimized codon frequency
according the invention as dsclosed herein; said synonymous coding sequence
being
associated with a control sequence comprising one translational initiator
sequence
selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-
mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier
disclosed)
and/or one translational termination sequence orientated in 5' towards 3'
direction
selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. More
preferably,
the nucleotide sequence comprises a synonymous coding sequence, which has an
optimized codon frequency according the invention as disclosed herein; said
synonymous coding sequence being associated with a control sequence comprising
one
translational initiator sequence selected from the following list: 5'-
mwChkyCAAA-3' and
5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3' (the ambiguity codes of m, w have
already
been earlier disclosed) and/or the following translational termination
sequence 5'-TAAA-
3'. Even more preferably, the nucleotide sequence comprises a synonymous
coding
sequence, which has an optimized codon frequency according the invention as
disclosed
herein; said synonymous coding sequence being associated with a control
sequence
comprising one translational initiator sequence selected from the following
list: 5'-
CACCGTCAAA-3' and 5'-CGCAGTCAAG-3' and/or one translational termination
sequence orientated in 5' towards 3' direction selected from the following
list: 5'-TAAG-3',
5'-TAGA-3' and 5'-TAAA-3'. Yet even more preferably, the nucleotide sequence
comprises a synonymous coding sequence, which has an optimized codon frequency
according the invention as disclosed herein; said synonymous coding sequence
being
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
22
associated with a control sequence comprising one translational initiator
sequence
selected from the following list: 5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-3' and/or
the
following translational termination sequence 5'-TAAA-3'. Yet even more
preferably, the
nucleotide sequence comprises a synonymous coding sequence, which has an
optimized codon frequency according the invention as disclosed herein; said
synonymous coding sequence being associated with the following translational
initiator
sequence 5'-CGCAGTCAAG-3' and/or the following translational termination
sequence 5'-
TAAA-3'. Most preferably, the nucleotide sequence comprises a synonymous
coding
sequence, which has an optimized codon frequency according the invention as
disclosed
herein; said synonymous coding sequence being associated with the following
translational initiator sequence 5'-CACCGTCAAA-3' and/or the following
translational
termination sequence 5'-TAAA-3'.
According to a most preferred embodiment, the nucleotide sequence of the
invention comprises a synonymous coding sequence, which has an optimized codon
frequency according the invention as disclosed herein and/or comprises the
following
translational initiator coding sequence 5'-GCTTCCTTC-3'; said synonymous
coding
sequence being associated with a control sequence comprising one translational
initiator
sequence selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3',
and
5'-mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier
disclosed)
and/or one translational termination sequence orientated in 5' towards 3'
direction
selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. More
preferably,
the nucleotide sequence comprises a synonymous coding sequence, which has an
optimized codon frequency according the invention as disclosed herein and/or
comprises
the following translational initiator coding sequence 5'-GCTTCCTTC-3'; said
synonymous
coding sequence being associated with a control sequence comprising one
translational
initiator sequence selected from the following list: 5'-mwChkyCAAA-3' and 5'-
mwChkyCACA-3', and 5'-mwChkyCAAG-3' (the ambiguity codes of m, w have already
been earlier disclosed) and/or the following translational termination
sequence 5'-TAAA-
3'. Even more preferably, the nucleotide sequence comprises a synonymous
coding
sequence, which has an optimized codon frequency according the invention as
disclosed
herein and/or comprises the following translational initiator coding sequence
5'-
GCTTCCTTC-3'; said synonymous coding sequence being associated with a control
sequence comprising one translational initiator sequence selected from the
following list:
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
23
5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-3' and/or one translational termination
sequence orientated in 5' towards 3' direction selected from the following
list: 5'-TAAG-3',
5'-TAGA-3' and 5'-TAAA-3'. Yet even more preferably, the nucleotide sequence
comprises a synonymous coding sequence, which has an optimized codon frequency
according the invention as disclosed herein and/or comprises the following
translational
initiator coding sequence 5'-GCTTCCTTC-3'; said synonymous coding sequence
being
associated with a control sequence comprising a translational initiator
sequence selected
from of the following list: 5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-3' and/or the
following translational termination sequence 5'-TAAA-3'.Yet even more
preferably, ihe
nucleotide sequence comprises a synonymous coding sequence, which has an
optimized codon frequency according the invention as disclosed herein and/or
comprises
the following translational initiator coding sequence 5'-GCTTCCTTC-3'; said
synonymous
coding sequence being associated with the following translational initiator
sequence 5'-
CGCAGTCAAG-3' and/or the following translational termination sequence 5'-TAAA-
3'.
Most preferably, the nucleotide sequence comprises a synonymous coding
sequence,
which has an optimized codon frequency according the invention as disclosed
herein
and/or comprises the following translational initiator coding sequence 5'-
GCTTCCTTC-3';
said synonymous coding sequence being associated with the following
translational
initiator sequence 5'-CACCGTCAAA-3' and/or the following translational
termination
sequence 5'-TAAA-3'.
Alternatively and according to another preferred embodiment of the invention,
the
nucleotide sequence of the invention comprises a coding sequence, said coding
sequence being associated with a control sequence comprising one translational
initiator
sequence selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3',
and
5'-mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier
disclosed).
More preferably, the nucleotide sequence comprises a coding sequence, said
coding
sequence being associated with a control sequence comprising a translational
initiator
sequence selected from the following list: 5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-
3'.
Even more preferably, the nucleotide sequence comprises a coding sequence,
said
coding sequence being associated with a control sequence comprising the
translational
initiator sequence 5'-CGCAGTCAAG-3'. Most preferably, the nucleotide sequence
comprises a coding sequence, said coding sequence being associated with a
control
sequence comprising the translational initiator sequence 5'-CACCGTCAAA-3'.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
24
Alternatively and according to another more preferred embodiment of the
invention, the nucleotide sequence comprises a coding sequence and/or
comprises the
following translational initiator coding sequence 5'-GCTTCCTTC-3', said coding
sequence being associated with a control sequence comprising one translational
initiator
sequence selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3',
and
5'-mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier
disclosed).
More preferably, the nucleotide sequence comprises a coding sequence and/or
comprises the following translational initiator coding sequence 5-GCTTCCTTC-
3', said
coding sequence being associated with a control sequence comprising one
translational
initiator sequence selected from the following list: 5'-CACCGTCAAA-3' and 5'-
CGCAGTCAAG-3'. Even more preferably, the nucleotide sequence comprises a
coding
sequence and/or comprises the following translational initiator coding
sequence 5'-
GCTTCCTTC-3', said coding sequence being associated with a control sequence
comprising the translational initiator sequence 5'-CGCAGTCAAG-3'. Most
preferably, the
nucleotide sequence comprises a coding sequence and/or comprises the following
translational initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence
being
associated with a control sequence comprising the translational initiator
sequence 5'-
CACCGTCAAA-3'.
Alternatively and according to another more preferred embodiment of the
invention, the nucleotide sequence comprises a coding sequence, said coding
sequence
being associated with a control sequence comprising a translational initiator
sequence
selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-
mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier
disclosed)
and/or one translational termination sequence orientated in 5' towards 3'
direction
selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. More
preferably,
the nucleotide sequence comprises a coding sequence, said coding sequence
being
associated with a control sequence comprising a translational initiator
sequence selected
from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-
3'
(the ambiguity codes of m, w have already been earlier disclosed) and/or the
following
translational termination sequence 5'-TAAA-3'. Even more preferably, the
nucleotide
sequence comprises a coding sequence, said coding sequence being associated
with a
control sequence comprising a translational initiator sequence selected from
the following
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
list: 5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-3' and/or one translational
termination
sequence orientated in 5' towards 3' direction selected from the following
list: 5'-TAAG-3',
5'-TAGA-3' and 5'-TAAA-3'. Yet even more preferably, the nucleotide sequence
comprises a coding sequence, said coding sequence being associated with a
control
5 sequence comprising a translational initiator sequence selected from the
following list: 5'-
CACCGTCAAA-3' and 5'-CGCAGTCAAG-3' and/or the following translational
termination
sequence 5'-TAAA-3'. Yet even more preferably, the nucleotide sequence
comprises a
coding sequence, said ooding sequence being associated with a translational
initiator
sequence 5'-CGCAGTCAAG-3' and/or one translational termination sequence
orientated
10 in 5' towards 3' direction selected from the following list: 5'-TAAG-3', 5'-
TAGA-3' and 5'-
TAAA-3'. Yet even more preferably, the nucleotide sequence comprises a coding
sequence, said coding sequence being associated with a translational initiator
sequence
5'-CGCAGTCAAG-3' and/or the following translational termination sequence 5'-
TAAA-3'.
Yet even more preferably, the nucleotide sequence comprises a coding sequence,
said
15 coding sequence being associated with a translational initiator sequence 5'-
CACCGTCAAA -3' and/or one translational termination sequence orientated in 5'
towards
3' direction selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-
TAAA-3'. Most
preferably, the nucleotide sequence comprises a coding sequence, said coding
sequence being associated with a translational initiator sequence 5'-
CACCGTCAAA -3'
20 and/or the following translational termination sequence 5'-TAAA-3'.
Alternatively and according to a most preferred embodiment of the invention,
the
nucleotide sequence comprises a coding sequence and/or comprises the following
translational initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence
being
25 associated with a control sequence comprising one translational initiator
sequence
selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-
mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier
disclosed)
and/or one translational termination sequence orientated in 5' towards 3'
direction
selected from the following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. More
preferably,
the nucleotide sequence comprises a coding sequence and/or comprises the
following
translational initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence
being
associated with a control sequence comprising one translational initiator
sequence
selected from the following list: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-
mwChkyCAAG-3' (the ambiguity codes of m, w have already been earlier
disclosed)
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
26
and/or the following translational termination sequence 5'-TAAA-3'. Even more
preferably,
the nucleotide sequence comprises a coding sequence and/or comprises the
following
translational initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence
being
associated with a control sequence comprising one translational initiator
sequence
selected from the following list: 5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-3' and/or
one
translational termination sequence orientated in 5' towards 3' direction
selected from the
following list: 5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. Yet even more
preferably, the
nucleotide sequence comprises a coding sequence and/or comprises the following
translational initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence
being
associated with a control sequence comprising a translational initiator
sequence selected
from the following list: 5'-CACCGTCAAA-3' and 5'-CGCAGTCAAG-3' and/or the
following
translational termination sequence 5'-TAAA-3'. Yet even more preferably, the
nucleotide
sequence comprises a coding sequence and/or comprises the following
translational
initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence being
associated
with a translational initiator sequence 5'-CGCAGTCAAG-3' and/or one
translational
termination sequence orientated in 5' towards 3' direction selected from the
following list:
5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. Yet even more preferably, the
nucleotide
sequence comprises a coding sequence and/or comprises the following
translational
initiator coding sequence 5'-GCTTCCTTC-3', said coding sequence being
associated
with a translational initiator sequence 5'-CGCAGTCAAG-3' and/or the following
translational termination sequence 5'-TAAA-3'. Most preferably, the nucleotide
sequence
comprises a coding sequence and/or comprises the following translational
initiator coding
sequence 5'-GCTTCCTTC-3', said coding sequence being associated with a
translational initiator sequence 5'- CACCGTCAAA -3' and/or the following
translational
termination sequence 5'-TAAA-3'.
Alternatively and according to another preferred embodiment of the invention,
the
nucleotide sequence of the invention comprises a coding sequence, said coding
sequence being associated with a control sequence comprising one translational
termination sequence orientated in 5' towards 3' direction selected from the
following list:
5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. More preferably, the nucleotide
sequence of the
invention comprises a coding sequence, said coding sequence being associated
with the
following translational termination sequence 5'-TAAA-3'.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
27
Alternatively and according to another preferred embodiment of the invention,
the
nucleotide sequence of the invention comprises a coding sequence and/or
comprises the
following translational initiator coding sequence 5'-GCTTCCTTC-3', said coding
sequence being associated with a control sequence comprising one translational
termination sequence orientated in 5' towards 3' direction selected from the
following list:
5'-TAAG-3', 5'-TAGA-3' and 5'-TAAA-3'. More preferably, the nucleotide
sequence
comprises a coding sequence and/or comprises the following translational
initiator coding
sequence 5'-GCTTCCTTC-3', said coding sequence being associated with the
following
translational termination sequence 5'-TAAA-3'.
In addition to the control sequences defined in the first aspect of the
invention,
other control sequences may be used. Such other control sequence may be an
appropriate promoter sequence, a nucleotide sequence, which is recognized by a
host
cell for expression of the nucleic acid sequence. The promoter sequence
contains
transcriptional control sequences, which mediate the expression of the
polypeptide. The
promoter may be any nucleic acid sequence, which shows transcriptional
activity in the
cell including mutant, truncated, and hybrid promoters, and may be obtained
from genes
encoding extracellular or intracellular polypeptides either homologous or
heterologous to
the cell.
The control sequence may also be a suitable transcription terminator sequence,
a
sequence recognized by a cell to terminate transcription. The terminator
sequence is
operably linked to the 3' terminus of the nucleic acid sequence encoding the
polypeptide.
Any terminator, which is functional in the cell, may be used in the present
invention.
Preferred terminators for filamentous fungal cells are obtained from the genes
encoding A. oryzae TAKA amylase, A. niger glucoamylase (glaA), A. nidulans
anthranilate synthase, A. niger alpha-glucosidase, trpC gene and Fusarium
oxysporum
trypsin-like protease.
The control sequence may also be a suitable leader sequence, a non-translated
region of a mRNA which is important for translation by the cell. The leader
sequence is
operably linked to the 5' terminus of the nucleic acid sequence encoding the
polypeptide.
Any leader sequence, which is functional in the cell, may be used in the
present invention.
Preferred leaders for filamentous fungal cells are obtained from the genes
encoding A. oryzae TAKA amylase and A. nidulans triose phosphate isomerase and
A.
niger gI aA.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
28
Other control sequences may be isolated from the Penicillium IPNS gene, or
pcbC gene, the beta tubulin gene. All the control sequences cited in WO
01/21779 are
herewith incorporated by reference.
The control sequence may also be a polyadenylation sequence, a sequence
which is operably linked to the 3' terminus of the nucleic acid sequence and
which, when
transcribed, is recognized by the cell as a signal to add polyadenosine
residues to
transcribed mRNA. Any polyadenylation sequence, which is functional in the
cell, may be
used in the present invention.
Preferred polyadenylation sequences for filamentous fungal cells are obtained
from the genes encoding A. oryzae TAKA amylase, A. niger glucoamylase, A.
nidulans
anthranilate synthase, Fusarium oxyporum trypsin-like protease and A. niger
alpha-
glucosidase.
The nucleotide sequence of the invention may be comprised in a nucleic acid
construct or expression vector.
Nucleic acid constructs
According to a third aspect, the invention relates to a nucleic acid construct
or
expression vector comprising at least one the nucleotide sequences defined in
the former
sections:
- a synonymous nucleotide coding sequence by using optimal codon
frequency and optionally modification of control sequences such as:
- one translational termination sequence orientated in 5' towards 3' direction
selected from the following list of sequences: TAAG, TAGA and TAAA, preferably
TAAA,
and/or
- one translational initiator coding sequence orientated in 5' towards 3'
direction selected from the following list of sequences: GCTACCCCC; GCTACCTCC;
GCTACCCTC; GCTACCTTC; GCTCCCCCC; GCTCCCTCC; GCTCCCCTC;
GCTCCCTTC; GCTGCCCCC; GCTGCCTCC; GCTGCCCTC; GCTGCCTTC;
GCTTCCCCC; GCTTCCTCC; GCTTCCCTC; and GCTTCCTTC, preferably GCT TCC
TTC, and/or
- a translational initiator sequence, said translational initiator sequence
comprising the nucleic acid sequence as defined by the consensus translational
initiator
sequence: 5'-mwChkyCAmv-3', using ambiguity codes for nucleotides: m(A/C);
r(A/G);
w(A/T); s(C/G); y(C/T); k(G/T); v(A/C/G); h(A/C/T); d(A/G/T); b(C/G/T);
n(A/C/G/T),
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
29
preferably the translational initiator sequence is one selected from the
following list: 5'-
mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-mwChkyCAAG-3'. These preferred
sequences correspond to any one of the following sequences: AACAGCCAAA;
AACAGTCAAA; AACATCCAAA; AACATTCAAA; AACCGCCAAA; AACCGTCAAA;
AACCTCCAAA; AACCTTCAAA; AACTGCCAAA; AACTGTCAAA; AACTTCCAAA;
AACTTTCAAA; ATCAGCCAAA; ATCAGTCAAA; ATCATCCAAA; ATCATTCAAA;
ATCCGCCAAA; ATCCGTCAAA; ATCCTCCAAA; ATCCTTCAAA; ATCTGCCAAA;
ATCTGTCAAA; ATCTTCCAAA; ATCTTTCAAA; CACAGCCAAA; CACAGTCAAA;
CACATCCAAA; CACATTCAAA; CACCGCCAAA; CACCGTCAAA; CACCTCCAAA;
CACCTTCAAA; CACTGCCAAA; CACTGTCAAA; CACTTCCAAA; CACTTTCAAA;
CTCAGCCAAA; CTCAGTCAAA; CTCATCCAAA; CTCATTCAAA; CTCCGCCAAA;
CTCCGTCAAA; CTCCTCCAAA; CTCCTTCAAA; CTCTGCCAAA; CTCTGTCAAA;
CTCTTCCAAA; CTCTTTCAAA; AACAGCCACA; AACAGTCACA; AACATCCACA;
AACATTCACA; AACCGCCACA; AACCGTCACA; AACCTCCACA; AACCTTCACA;
AACTGCCACA; AACTGTCACA; AACTTCCACA; AACTTTCACA; ATCAGCCACA;
ATCAGTCACA; ATCATCCACA; ATCATTCACA; ATCCGCCACA; ATCCGTCACA;
ATCCTCCACA; ATCCTTCACA; ATCTGCCACA; ATCTGTCACA; ATCTTCCACA;
ATCTTTCACA; CACAGCCACA; CACAGTCACA; CACATCCACA; CACATTCACA;
CACCGCCACA; CACCGTCACA; CACCTCCACA; CACCTTCACA; CACTGCCACA;
CACTGTCACA; CACTTCCACA; CACTTTCACA; CTCAGCCACA; CTCAGTCACA;
CTCATCCACA; CTCATTCACA; CTCCGCCACA; CTCCGTCACA; CTCCTCCACA;
CTCCTTCACA; CTCTGCCACA; CTCTGTCACA; CTCTTCCACA; CTCTTTCACA;
AACAGCCAAG; AACAGTCAAG; AACATCCAAG; AACATTCAAG; AACCGCCAAG;
AACCGTCAAG; AACCTCCAAG; AACCTTCAAG; AACTGCCAAG; AACTGTCAAG;
AACTTCCAAG; AACTTTCAAG; ATCAGCCAAG; ATCAGTCAAG; ATCATCCAAG;
ATCATTCAAG; ATCCGCCAAG; ATCCGTCAAG; ATCCTCCAAG; ATCCTTCAAG;
ATCTGCCAAG; ATCTGTCAAG; ATCTTCCAAG; ATCTTTCAAG; CACAGCCAAG;
CACAGTCAAG; CACATCCAAG; CACATTCAAG; CACCGCCAAG; CACCGTCAAG;
CACCTCCAAG; CACCTTCAAG; CACTGCCAAG; CACTGTCAAG; CACTTCCAAG;
CACTTTCAAG; CTCAGCCAAG; CTCAGTCAAG; CTCATCCAAG; CTCATTCAAG;
CTCCGCCAAG; CTCCGTCAAG; CTCCTCCAAG; CTCCTTCAAG; CTCTGCCAAG;
CTCTGTCAAG; CTCTTCCAAG or CTCTTTCAAG. More preferably, the translational
initiator sequence is 5'-CACCGTCAAA-3' or 5'-CGCAGTCAAG-3'.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
According to another preferred embodiment, the nucleic acid construct or
expression vector comprises a translational initiator sequence, said
translational initiator
sequence comprising the nucleic acid sequence as defined by the consensus
translational initiator sequence: 5'-mwChkyCAmv-3', using ambiguity codes for
5 nucleotides: m (A/C); r(A/G); w(A/T); s(C/G); y(C/T); k(G/T); v(A/C/G);
h(A/C/T); d
(A/G/T); b(C/G/T); n(A/C/G/T), preferably the translational initiator sequence
is selected
amongst the group consisting of: 5'-mwChkyCAAA-3', 5'-mwChkyCACA-3', and 5'-
mwChkyCAAG-3'. These preferred sequences correspond to any one of the
following
sequences: AACAGCCAAA; AACAGTCAAA; AACATCCAAA; AACATTCAAA;
10 AACCGCCAAA; AACCGTCAAA; AACCTCCAAA; AACCTTCAAA; AACTGCCAAA;
AACTGTCAAA; AACTTCCAAA; AACTTTCAAA; ATCAGCCAAA; ATCAGTCAAA;
ATCATCCAAA; ATCATTCAAA; ATCCGCCAAA; ATCCGTCAAA; ATCCTCCAAA;
ATCCTTCAAA; ATCTGCCAAA; ATCTGTCAAA; ATCTTCCAAA; ATCTTTCAAA;
CACAGCCAAA; CACAGTCAAA; CACATCCAAA; CACATTCAAA; CACCGCCAAA;
15 CACCGTCAAA; CACCTCCAAA; CACCTTCAAA; CACTGCCAAA; CACTGTCAAA;
CACTTCCAAA; CACTTTCAAA; CTCAGCCAAA; CTCAGTCAAA; CTCATCCAAA;
CTCATTCAAA; CTCCGCCAAA; CTCCGTCAAA; CTCCTCCAAA; CTCCTTCAAA;
CTCTGCCAAA; CTCTGTCAAA; CTCTTCCAAA; CTCTTTCAAA; AACAGCCACA;
AACAGTCACA; AACATCCACA; AACATTCACA; AACCGCCACA; AACCGTCACA;
20 AACCTCCACA; AACCTTCACA; AACTGCCACA; AACTGTCACA; AACTTCCACA;
AACTTTCACA; ATCAGCCACA; ATCAGTCACA; ATCATCCACA; ATCATTCACA;
ATCCGCCACA; ATCCGTCACA; ATCCTCCACA; ATCCTTCACA; ATCTGCCACA;
ATCTGTCACA; ATCTTCCACA; ATCTTTCACA; CACAGCCACA; CACAGTCACA;
CACATCCACA; CACATTCACA; CACCGCCACA; CACCGTCACA; CACCTCCACA;
25 CACCTTCACA; CACTGCCACA; CACTGTCACA; CACTTCCACA; CACTTTCACA;
CTCAGCCACA; CTCAGTCACA; CTCATCCACA; CTCATTCACA; CTCCGCCACA;
CTCCGTCACA; CTCCTCCACA; CTCCTTCACA; CTCTGCCACA; CTCTGTCACA;
CTCTTCCACA; CTCTTTCACA; AACAGCCAAG; AACAGTCAAG; AACATCCAAG;
AACATTCAAG; AACCGCCAAG; AACCGTCAAG; AACCTCCAAG; AACCTTCAAG;
30 AACTGCCAAG; AACTGTCAAG; AACTTCCAAG; AACTTTCAAG; ATCAGCCAAG;
ATCAGTCAAG; ATCATCCAAG; ATCATTCAAG; ATCCGCCAAG; ATCCGTCAAG;
ATCCTCCAAG; ATCCTTCAAG; ATCTGCCAAG; ATCTGTCAAG; ATCTTCCAAG;
ATCTTTCAAG; CACAGCCAAG; CACAGTCAAG; CACATCCAAG; CACATTCAAG;
CACCGCCAAG; CACCGTCAAG; CACCTCCAAG; CACCTTCAAG; CACTGCCAAG;
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
31
CACTGTCAAG; CACTTCCAAG; CACTTTCAAG; CTCAGCCAAG; CTCAGTCAAG;
CTCATCCAAG; CTCATTCAAG; CTCCGCCAAG; CTCCGTCAAG; CTCCTCCAAG;
CTCCTTCAAG; CTCTGCCAAG; CTCTGTCAAG; CTCTTCCAAG or CTCTTTCAAG.
More preferably, the translational initiator sequence is 5'-CACCGTCAAA-3' or
5'-
CGCAGTCAAG-3'.
"Nucleic acid construct " is defined herein as a nucleic acid molecule, either
single-or double-stranded, which is isolated from a naturally occurring gene
or which has
been modified to contain segments of nucleic acid which are combined and
juxtaposed in
a manner which would not otherwise exist in nature. The term nucleic acid
construct is
synonymous with the term expression cassette or expression vector when the
nucleic
acid construct contains all the control sequences required for expression of a
coding
sequence.
Manipulation of the nucleotide sequence encoding a polypeptide prior to its
insertion into a nucleic acid construct or expression vector may be desirable
or
necessary depending on the nucleic acid construct or expression vector. The
techniques
for modifying nucleic acid sequences utilizing cloning methods are well known
in the art.
The present invention also relates to recombinant expression vectors
comprising
the nucleotide sequences of the invention, a promoter, and transcriptional and
translational stop signals. The various nucleic acid and control sequences
described
above may be joined together to produce a recombinant expression vector which
may
include one or more convenient restriction sites to allow for insertion or
substitution of the
nucleic acid sequence encoding the polypeptide at such sites.
Alternatively, the nucleotide sequence encoding the polypeptide may be
expressed by inserting the nucleotide sequence or nucleic acid construct
comprising the
sequence into an appropriate vector for expression. In creating the expression
vector, the
coding sequence is located in the vector in such a fashion that the coding
sequence is
operatively associated with the appropriate control sequences for expression,
and
optional secretion.
The recombinant expression vector may be any vector (e.g., a plasmid or
virus),
which can be conveniently subjected to recombinant DNA procedures and can
confer
expression of the nucleic acid sequence encoding the polypeptide. The choice
of the
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
32
vector will typically depend on the compatibility of the vector with the
filamentous fungal
cell into which the vector is to be introduced. The vectors may be linear or
closed circular
plasmids. The vector may be an autonomously replicating vector, i.e., a
vector, which
exists as an extrachromosomal entity, the replication of which is independent
of
chromosomal replication, e.g., a plasmid, an extrachromosomal element, a
minichromosome, or an artificial chromosome. An autonomously maintained
cloning
vector may comprise the AMA1-sequence (see e.g. Aleksenko and Clutterbuck
(1997),
Fungal Genet. Biol. 21: 373-397).
Alternatively, the vector may be one which, when introduced into the fungal
cell, is
integrated into the genome and replicated together with the chromosome (s)
into which it
has been integrated. The integrative cloning vector may integrate at random or
at a
predetermined target locus in the chromosomes of the fungal host cell. In a
preferred
embodiment of the invention, the integrative cloning vector comprises a DNA
fragment,
which is homologous to a DNA sequence in a predetermined target locus in the
genome
of the fungal host cell for targeting the integration of the cloning vector to
this
predetermined locus. In order to promote targeted integration, the cloning
vector is
preferably linearized prior to transformation of the host cell. Linearization
is preferably
performed such that at least one but preferably either end of the cloning
vector is flanked
by sequences homologous to the target locus. The length of the homologous
sequences
flanking the target locus is preferably at least 30bp, preferably at least 50
bp, preferably at
least 0.1 kb, even preferably at least 0.2kb, more preferably at least 0.5 kb,
even more
preferably at least 1 kb, most preferably at least 2 kb. Preferably, the DNA
sequence in
the cloning vector, which is homologous to the target locus is derived from a
highly
expressed locus meaning that it is obrived from a gene, which is capable of
high
expression level in the filamentous fungal host cell. A gene capable of high
expression
level, i.e. a highly expressed gene, is herein defined as a gene whose mRNA
can make
up at least 0.5% (w/w) of the total cellular mRNA, e.g. under induced
conditions, or
alternatively, a gene whose gene product can make up at least 1%(w/w) of the
total
cellular protein, or, in case of a secreted gene product, can be secreted to a
level of at
least 0.1 g/I (as described in EP 357 127 B1). A number of preferred highly
expressed
fungal genes are given by way of example: the amylase, glucoamylase, alcohol
dehydrogenase, xylanase, glyceraldehyde-phosphate dehydrogenase or
cellobiohydrolase (cbh) genes from Aspergilli or Trichoderma. Most preferred
highly
expressed genes for these purposes are a glucoamylase gene, preferably an A.
niger
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
33
glucoamylase gene, an A. oryzae TAKA-amylase gene, an A. nidulans gpdA gene, a
Trichoderma reesei cbh gene, preferably cbhl. More than one copy of a nucleic
acid
sequence encoding a polypeptide may be inserted into the host cell to increase
production of the gene product. This can be done, preferably by integrating
into its
genome copies of the DNA sequence, more preferably by targeting the
integration of the
DNA sequence at one of the highly expressed locus defined in the former
paragraph.
Alternatively, this can be done by including an amplifiable selectable marker
gene with the
nucleic acid sequence where cells containing amplified copies of the
selectable marker
gene, and thereby additional copies of the nucleic acid sequence, can be
selected for by
cultivating the cells in the presence of the appropriate selectable agent. To
increase even
more the number of copies of the DNA sequence to be over expressed the
technique of
gene conversion as described in W098/46772 may be used.
The vector system may be a single vector or plasmid or two or more vectors or
plasmids, which together contain the total DNA to be introduced into the
genome of the
filamentous fungal cell, or a transposon.
The vectors preferably contain one or more selectable markers, which permit
easy selection of transformed cells. A selectable marker is a gene the product
of which
provides for biocide or viral resistance, resistance to heavy metals,
prototrophy to
auxotrophs, and the like. A selectable marker for use in a filamentous fungal
cell may be
selected from the group including, but not limited to, amdS (acetamidase),
argB (ornithine
carbamoyltransf erase), bar (phosphinothricinacetyltransferase), bleA
(phleomycin
binding), hygB (hygromycinphosphotransferase), niaD (nitrate reductase), pyrG
(orotidine-5'-phosphate decarboxylase), sC (sulfate adenyltransferase), and
trpC
(anthranilate synthase), as well as equivalents from other species. Preferred
for use in an
Aspergillus and Penicillium cell are the amdS (EP 635574 B1, WO 97/06261) and
pyrG
genes of A. nidulans or A. oryzae and the bar gene of Streptomyces
hygroscopicus.
More preferably an amdS gene is used, even more preferably an amdS gene from
A.
nidulans or A. niger. A most preferred selection marker gene is the A.
nidulans amdS
coding sequence fused to the A. nidulans gpdA promoter (see EP 635574 B1).
AmdS
genes from other filamentous fungi may also be used (WO 97/06261).
The procedures used to ligate the elements described above to construct the
recombinant expression vectors of the present invention are well known to one
skilled in
the art (see, e.g., Sambrook et al., 1989, supra).
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
34
Host cells
According to a fourth aspect, the invention relates to a filamentous fungal
host
cell. The filamentous fungal host cell of the invention may be any filamentous
fungal host
cell host cell known to the skilled person.
"Filamentous fungi" include all filamentous forms of the subdivision Eumycota
and
Oomycota (as defined by Hawksworth et al., 1995, supra). The filamentous fungi
are
characterized by a mycelia wall composed of chitin, cellulose, glucan,
chitosan, mannan,
and other complex polysaccharides. Vegetative growth is by hyphal elongation
and
carbon catabolism is obligatory aerobic. Filamentous fungal strains include,
but are not
limited to, strains of Acremonium, Aspergillus, Aureobasidium, Cryptococcus,
Chrysosporum Filibasidium, Fusarium, Humicola, Magnaporthe, Mucor,
Myceliophthora,
Neocallimastix, Neurospora, Paecilomyces, Penicillium, Piromyces,
Schizophyllum,
Talaromyces, Thermoascus, Thielavia, Tolypocladium, and Trichoderma.
Strains of Aspergillus and teleomorphs thereof are readily accessible to the
public
in a number of culture collections, such as the American Type Culture
Collection (ATCC),
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSM),
Centraalbureau Voor Schimmelcultures (CBS), and Agricultural Research Service
Patent
Culture Collection, Northern Regional Research Center (NRRL) Aspergillus
nigerCBS
513.88, Aspergillus oryzae ATCC 20423, IFO 4177, ATCC 1011, ATCC 9576,
ATCC14488-14491, ATCC 11601, ATCC12892, P. chrysogenum CBS 455.95,
Penicillium citrinum ATCC 38065, Penicillium chrysogenum P2, Acremonium
chrysogenum ATCC 36225 or ATCC 48272, Trichoderma reesei ATCC 26921 or ATCC
56765 or ATCC 26921, Aspergillus sojae ATCC1 1906, Chrysosporium lucknowense
ATCC44006 and derivatives thereof.
Preferably, the filamentous fungal host cell of the invention comprises at
least one
copy of the nucleic acid construct of the third aspect of the invention.
According to a preferred embodiment, the coding and/or control sequences
present in the nucleic acid construct are native to the filamentous fungal
host cell before
modification of the coding and/or control sequences according to the first and
second
aspect of the invention.
According to another preferred embodiment, the coding and/or control sequences
present in the nucleic acid construct are heterologous to the filamentous
fungal host cell
before modification of the coding and/or control sequences according to the
first and
second aspect of the invention.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
According to a more preferred embodiment, the filamentous fungal host cell of
the
invention, comprising a given copy number of the nucleic acid construct of the
third
aspect of the invention is a filamentous fungal cell, wherein the expression
of the product
encoded by said nucleic acid construct is enhanced as compared to the
production of the
5 same product encoded by the corresponding nucleic acid construct comprising
the
corresponding native nucleotide sequences, said corresponding nucleic acid
construct
being present in the same copy number in the corresponding filamentous fungal
host cell.
Preferably, the modification d the nucleotide sequences present in the nucleic
acid
construct or expression vector of the third aspect of the invention results in
an increase
10 by at least 1%, 5%, 10%, 25%, 50%, 100%, 200%, 300%, 400% more preferably
at least
500% of the yield of the compound of interest produced by the filamentous
fungal host
cell of the invention comprising a given copy number of the nucleic acid
construct of the
third aspect of the invention, as compared to the production of the
corresponding nucleic
acid construct comprising the corresponding native nucleotide sequences, said
15 corresponding nucleic acid construct being present in the same copy number
in the
corresponding filamentous fungal host cell.
The increase in yield of the compound of interest to be produced may be
determined by measuring the amount of compound produced by the filamentous
fungal
host cell of the invention and comparing it to the compound of interest
produced by the
20 corresponding filamentous fungal host cell. Determining the yield of
compound of interest
produced may be performed by measuring inter alia the amount of mRNA
transcribed
from the (synonymous) nucleotide coding sequence, the amount of polypeptide
encoded
by the mRNA, or the amount of compound (e.g. metabolite) in which' production
the
polypeptide encoded by the synonymous nucleotide coding sequence is involved
with.
25 Examples of methods known to the skilled person to determine the amount of
mRNA
include, but are not limited to Northern blot, Quantitative PCR, Real Time
PCR, and
micro-array analyses. The amount of polypeptide can inter alia be determined
using
protein measurement assays known to the skilled person. When the polypeptide
is an
enzyme, the amount of polypeptide can be measured using an activity assay
specific for
30 the concerned enzyme. The skilled person will know which assay to select
for a specific
enzyme. A preferred assay to determine the yield of the compound of interest
to be
produced is an activity assay specific for the concerned enzyme.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
36
According to a more preferred embodiment, the host cell of the present
invention
is a cell belonging to a species selected from the group consisting of an
Aspergillus,
Penicillium, Fusarium, Chrysosporum or Trichoderma species, most preferably a
species selected from the group consisting of Aspergillus niger, Aspergillus
oryzae,
Aspergillus sojae, Aspergillus terreus, Chrysosporum lucknowense, Trichoderma
reesei
or Penicillium chrysogenum. A most preferred Aspergillus niger host cell is
CBS513.88
or derivatives thereof.
The host cell may be a wild type filamentous fungus host cell or a variant, a
mutant or a genetically modified filamentous fungus host cell. In a preferred
embodiment
of the invention the host cell is a protease deficient or protease minus
strain. This may be
the protease deficient strain Aspergillus oryzae JaL 125 having the alkaline
protease gene
named "alp" deleted (described in WO 97/35956 or EP 429 490), or the
tripeptidyl-
aminopeptidases (TPAP) deficient strain of A. niger, disclosed in WO 96/14404.
Further,
also host cell with reduced production of the transcriptional activator (prtT)
as described
in WO 01/68864 is contemplated according to the invention. Another
specifically
contemplated host strain is the Aspergillus oryzae BECh2, where the three TAKA
amylase genes present in the parent strain IF04177 has been inactivated. In
addition, two
proteases, the alkaline protease and neutral metalloprotease 11 have been
destroyed by
gene disruption. The ability to form the metabolites cyclopiazonic acid and
kojic acid has
been destroyed by mutation. BECh2 is described in WO 00/39322 and is derived
from
JaL228 (described in WO 98/12300), which again was a mutant of IF04177
disclosed in
US 5,766, 912 as A1560.
Optionally, the filamentous fungal host cell comprises an elevated unfolded
protein
response (UPR) compared to the wild type cell to enhance production abilities
of a
polypeptide of interest. UPR may be increased by techniques described in
US2004/0186070A1 and/or US2001 /0034045A1 and/or W001 /72783A2 and/or
W02005/123763. More specifically, the protein level of HAC1 and/or IRE1 and/or
PTC2
has been modulated, and/or the SEC61 protein has been engineered in order to
obtain a
host cell having an elevated UPR.
Alternatively, or in combination with an elevated UPR, the host cell is
genetically
modified to obtain a phenotype displaying lower protease expression and/or
protease
secretion compared to the wild-type cell in order to enhance production
abilities of a
polypeptide of interest. Such phenotype may be obtained by deletion and/or
modification
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
37
and/or inactivation of a transcriptional regulator of expression of proteases.
Such a
transcriptional regulator is e.g. prtT. Lowering expression of proteases by
modulation of
prtT may be performed by techniques described in US2004/0191864A1.
Alternatively, or in combination with an elevated UPR and/or a phenotype
displaying lower protease expression and/or protease secretion, the host cell
displays an
oxalate deficient phenotype in order to enhance the yield of production of a
polypeptide of
interest. An oxalate deficient phenotype may be obtained by techniques
described in
W02004/070022A2.
Alternatively, or in combination with an elevated UPR and/or a phenotype
displaying lower protease expression and/or protease secretion and/or oxalate
deficiency,
the host cell displays a combination of phenotypic differences compared to the
wild cell to
enhance the yield of production of the polypeptide of interest. These
differences may
include, but are not limited to, lowered expression of glucoamylase and/or
neutral alpha-
amylase A and/or neutral alpha-amylase B, alpha-1, 6transglucosidase,
protease, and
oxalic acid hydrolase. Said phenotypic differences displayed by the host cell
may be
obtained by genetic modification according to the techniques described in
US2004/0191864A1.
Alternatively, or in combination with phenotypes described here above, the
efficiency of targeted integration of a nucleic acid construct into the genome
of the host
cell by homologous recombination, i.e. integration in a predetermined target
locus, is
preferably increased by augmented homologous recombination abilities of the
host cell.
Such phenotype of the cell preferably involves a deficient hdfA or hdfB gene
as described
in W02005/095624. W02005/095624 discloses a preferred method to obtain a
filamentous fungal cell comprising increased efficiency of targeted
integration.
The introduction of an expression vector or a nucleic acid construct into a
filamentous fungal cell may involve a process consisting of protoplast
formation,
transformation of the protoplasts, and regeneration of the cell wall in a
manner known per
se. Suitable procedures for transformation of Aspergillus cells are described
in EP 238
023 and Yelton et al., 1984, Proceedings of the National Academy of Sciences
USA
81:1470-1474. A suitable method of transforming Fusarium species is described
by
Malardier et al., 1989, Gene 78:147156 or in WO 96/00787. The expression
vector or
nucleic acid construct that can be used were already described under the
corresponding
sections.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
38
Producing a compound of interest
The present invention may be used to produce a compound of interest. The
compound of interest is preferably a polypeptide. Alternatively, the compound
of interest
may be a metabolite. In this case, a nucleotide sequence encoding an enzyme
involved in
the synthesis of the metabolite is modified according to the invention. The
term
"metabolite" encompasses both primary and secondary metabolites; the
metabolite may
be any metabolite. A preferred metabolite is citric acid. Another preferred
metabolite is a
carotenoid. The metabolite may be encoded by one or more genes, such as in a
biosynthetic or metabolic pathway. Primary metabolites are products of primary
or
general metabolism of a cell, which are concerned with energy metabolism,
growth, and
structure. Secondary metabolites are products of secondary metabolism (see,
for
example, R. B. Herbert, The Biosynthesis of Secondary Metabolites, Chapman and
Hall,
New York, 1981). The primary metabolite may be, but is not limited to, an
amino acid,
fatty acid, nucleoside, nucleotide, sugar, triglyceride, or vitamin. The
secondary
metabolite may be, but is not limited to, an alkaloid, coumarin, flavonoid,
polyketide,
quinine, steroid, peptide, or terpene. The secondary metabolite may be an
antibiotic,
antifeedant, attractant, bacteriocide, fungicide, hormone, insecticide, or
rodenticide.
Preferred antibiotics are cephalosporins and beta-lactams.
Alternatively, the compound of interest may also be the product of a
selectable
marker gene. A selectable marker gene is a gene the product of which provides
for
biocide or viral resistance, resistance to heavy metals, prototrophy to
auxotrophs, and the
like. In this case, a nucleotide sequence encoding a selectable marker gene
product is
modified according to the invention. Selectable markers include, but are not
limited to,
amdS (acetamidase), argB (ornithinecarbamoyltransferase), bar
(phosphinothricinacetyltransferase), hygB (hygromycin phosphotransferase),
niaD
(nitratereductase), pyrG (orotidine-5'-phosphate decarboxylase), sC (sulfate
adenyltransferase), trpC (anthranilate synthase), ble (phleomycin resistance
protein), as
well as equivalents thereof.
When the compound of interest is a polypeptide, the polypeptide may be any
polypeptide whether native or heterologous (or not native) to the cell. As
soon as the DNA
sequence encoding the polypeptide and the control DNA sequences operatively
associated thereto are known, these native or not native DNA sequences are
modified
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
39
according to the invention (see section DNA sequence), cloned into an
appropriate DNA
construct or expression vector and transformed into a chosen host. The nucleic
acid
sequence encoding a heterologous polypeptide may be obtained from any
prokaryotic,
eukaryotic, plant, or other source. For purposes of the present invention, the
term
"obtained from" as used herein in connection with a given source shall mean
that the
polypeptide is produced by the source or by a cell in which a gene from the
source has
been inserted.
The term "heterologous polypeptide" is defined herein as a polypeptide, which
is
not produced by a wild-type cell (not native). The term "polypeptide" is not
meant herein to
refer to a specific length of the encoded produce and therefore encompasses
peptides,
oligopeptides and proteins. The polypeptide may also be a recombinant
polypeptide,
which is a polypeptide native to a cell, which is encoded by an optimized
nucleic acid
sequence for example and, which additionally may comprise one or more control
sequences, foreign to the nucleic acid sequence, which is involved in the
production of
the polypeptide. The polypeptide may be a wild-type polypeptide or a variant
thereof. The
polypeptide may also be a hybrid polypeptide, which contains a combination of
partial or
complete polypeptide sequences obtained from at least two different
polypeptides where
one or more of the polypeptides may be heterologous to the cell. Polypeptides
further
include naturally occurring allelic and engineered variations of the above-
mentioned
polypeptides.
Preferably, the polypeptide is secreted outside the filamentous fungal host
cell. In
a preferred embodiment, the polypeptide is an antibody or portions thereof, an
antigen, a
clotting factor, an enzyme, a hormone or a hormone variant, a receptor or
portions
thereof, a regulatory protein, a structural protein, a reporter, or a
transport protein,
intracellular protein, protein involved in secretion process, protein involved
in folding
process, chaperone, peptide amino acid transporter, glycosylation factor,
transcription
factor. In a preferred embodiment, the polypeptide is secreted into the
extracellular
environment.
In a more preferred embodiment, the enzyme is an oxidoreductase, transferase,
hydrolase, lyase, isomerase, ligase, catalase, cellulase, chitinase, cutinase,
deoxyribonuclease, dextranase, esterase.
In an even more preferred embodiment, the polypeptide is a carbohydrase, e.g.,
cellulases such as endoglucanases, f3-glucanases, cellobiohydrolases or 13-
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
glucosidases, hemicellulases or pectinolytic enzymes such as xylanases,
xylosidases,
mannanases, galactanases, galactosidases, pectin methyl esterases, pectin
lyases,
pectate lyases, endo polygalacturonases, exopolygalacturonases
rhamnogalacturonases, arabanases, arabinofuranosidases, arabinoxylan
hydrolases,
5 galacturonases, lyases, or amylolytic enzymes; hydrolase, isomerase, or
ligase,
phosphatases such as phytases, esterases such as lipases, proteolytic enzymes,
oxidoreductases such as oxidases, transferases, or isomerases. More
preferably, the
desired gene encodes a phytase. In an even more preferred embodiment, the
polypeptide
is an aminopeptidase, amylase, carbohydrase, carboxypeptidase, endo-protease,
10 metallo-protease, serine-protease catalase, chitinase, cutinase,
cyclodextrin
glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-
galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase,
haloperoxidase,
proteolytic enzyme, invertase, laccase, lipase, mannosidase, mutanase,
oxidase,
pectinolytic enzyme, peroxidase, phospholipase, polyphenoloxidase,
ribonuclease,
15 transglutaminase, or glucose oxidase, hexose oxidase, monooxygenase.
In another even more preferred embodiment, the polypeptide is human insulin or
an analog thereof, human growth hormone, erythropoietin, tissue plasminogen
activator
(tPA) or insulinotropin.
20 The polypeptide may also be an intracellular protein or enzyme such as for
example a chaperone, protease or transcription factor. An example of this is
described in
Appl. Microbiol. Biotechnol. 1998 Oct; 50(4):447-54 ("Analysis of the role of
the gene bipA,
encoding the major endoplasmic reticulum chaperone protein in the secretion of
homologous and heterologous proteins in black Aspergilli. Punt PJ, van Gemeren
IA,
25 Drint-Kuijvenhoven J, Hessing JG, van Muijlwijk-Harteveld GM, Beijersbergen
A, Verrips
CT, van den Hondel CA). This can be used for example to improve the efficiency
of a
host cell as protein producer if this polypeptide, such as a chaperone,
protease or
transcription factor, was known to be a limiting factor in protein production.
Alternatively, the intracellular polypeptide is an enzyme involved in the
production
30 of a given secondary metabolite such as a carotenoid or an antibiotica.
The present invention may also be used for the recombinant production of
polypeptides, which are native to the cell. The native polypeptide may be
recombinantly
produced if one modifies the coding and/or control nucleotide sequences as
defined in
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
41
the corresponding earlier sections. For example, the coding sequence is
modified by
using the optimized codons frequency as defined earlier to code any amino acid
to
improve the expression level of the native or naturally occurring nucletide
sequence.
Optionally, the synonymous coding sequence obtained may be placed under the
control
of a different promoter to enhance expression of the polypeptide, to expedite
export of a
native polypeptide of interest outside the cell by use of a signal sequence of
the invention,
and to increase the copy number of a gene encoding the polypeptide normally
produced
by the cell. The present invention also encompasses, within the scope of the
term
"heterologous polypeptide", such recombinant production of polypeptides native
to the
cell, to the extent that such expression involves the use of genetic elements
not native to
the cell, or use of native elements which have been manipulated to function in
a manner
that do not normally occur in the filamentous fungal cell. The techniques used
to isolate
or clone a nucleic acid sequence encoding a heterologous polypeptide are known
in the
art and include isolation from genomic DNA, preparation from cDNA, or a
combination
thereof.
In the methods of the present invention, heterologous polypeptides may also
include a fused or hybrid polypeptide in which another polypeptide is fused at
the N-
terminus or the C-terminus of the polypeptide or fragment thereof. A fused
polypeptide is
produced by fusing a nucleic acid sequence (or a portion thereof) encoding one
polypeptide to a nucleic acid sequence (or a portion thereof) encoding another
polypeptide.
Techniques for producing fusion polypeptides are known in the art, and
include,
ligating the coding sequences encoding the polypeptides so that they are in
frame and
expression of the fused polypeptide is under control of the same promoter (s)
and
terminator. The hybrid polypeptides may comprise a combination of partial or
complete
polypeptide sequences obtained from at least two different polypeptides
wherein one or
more may be heterologous to the mutant fungal cell. An isolated nucleic acid
sequence
encoding a heterologous polypeptide of interest may be manipulated in a
variety of ways
to provide for expression of the polypeptide. Expression will be understood to
include any
step involved in the production of the polypeptide including, but not limited
to,
transcription, posttranscriptional modification, translation, post-
translational modification,
and secretion. Manipulation of the nucleic acid sequence encoding a
polypeptide prior to
its insertion into a vector may be desirable or necessary depending on the
expression
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
42
vector. The techniques for modifying nucleic acid sequences utilizing cloning
methods
are well known in the art.
The compound of interest described in the section here above may be produced
in a filamentous fungal host cells provided by the invention.
Thus, according to another aspect, the invention relates to methods of
producing
a compound of interest in a filamentous fungal host cell of the present
invention,
comprising:
(a) cultivating the filamentous fungal host cell as defined in the former
section
in a nutrient medium suitable for production of the compound of interest; and
(b) recovering the compound of interest from the nutrient medium of the
filamentous fungal host cell.
The filamentous fungal host cells of the present invention are cultivated in a
nutrient medium suitable for production of the compound of interest using
methods
known in the art. For example, the cells may be cultivated by shake flask
cultivation,
small-scale or large-scale fermentation (including continuous, batch, fed-
batch, or solid
state fermentations) in laboratory or industrial fermentors performed in a
suitable medium
and under conditions allowing the compound of interest to be expressed and/or
isolated.
The cultivation takes place in a suitable nutrient medium comprising carbon
and nitrogen
sources and inorganic salts, using procedures known in the art (see, e.g.,
Bennett, J. W.
and LaSure, L., eds., More Gene Manipulations in Fungi, Academic Press, CA,
1991).
Suitable media are available from commercial suppliers or may be prepared
using
published compositions (e.g., in catalogues of the American Type Culture
Collection). If the compound of interest is secreted into the nutrient medium,
the
polypeptide can be recovered directly from the medium. If the compound of
interest is not
secreted, it is recovered from cell lysates.
The resulting compound of interest may be isolated by methods known in the
art.
For example, the polypeptide may be isolated from the nutrient medium by
conventional
procedures including, but not limited to, centrifugation, filtration,
extraction, spray drying,
evaporation, or precipitation. The isolated compound of interest may then be
further
purified by a variety of procedures known in the art including, but not
limited to,
chromatography (e.g., ion exchange, affinity, hydrophobic, chromatofocusing,
and size
exclusion), electrophoretic procedures (e.g., preparative isoelectric
focusing, differential
solubility (e.g., ammonium sulfate precipitation), or extraction (see, e.g.,
Protein
Purification, J.-C. Janson and Lars Ryden, editors, VCH Publishers, New York,
1989).
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
43
The compound of interest may be detected using methods known in the art that
are specific for the polypeptide. These detection methods may include use of
specific
antibodies, formation of an enzyme product, disappearance of an enzyme
substrate, or
SDS PAGE. For example, an enzyme assay may be used to determine the activity
if the
compound of interest is an enzyme. Procedures for determining enzyme activity
are
known in the art for many enzymes.
In the method of the invention, the yield of the compound of interest produced
by
the filamentous fungal host of the invention comprising a given copy number of
the
nucleic acid construct of the third aspect of the invention is preferably
increased by at
least 1%, 5%, 10%, 25%, 50%, 100%, 200%, 300%, 400% more preferably at least
500%, as compared to the production of the corresponding nucleic acid
construct
comprising the corresponding native nucleotide sequences, said corresponding
nucleic
acid construct being present in the same copy number in the corresponding
filamentous
fungal host cell. Preferably, the filamentous fungal host cell of the present
invention is an
Aspergillus, Trichoderma, Fusarium, Chrysosporum or Penicillium host cell.
More
preferably the filamentous fungal host cell is an Aspergillus niger,
Aspergillus oryzae,
Aspergillus sojae, Aspergillus terreus, Chrysosporum lucknowense, Trichoderma
reesei
or Penicillium chrysogenum host cell. A most preferred Aspergillus niger host
cell is
CBS513.88 or derivatives thereof.
In another preferred embodiment, the yield of the compound of interest
produced
by the filamentous fungal host of the invention comprising a given copy rumber
of the
nucleic acid construct of the third aspect of the invention, is preferably 0.1
g per liter, 0.2
g, 0.3 g, 0.4 g, more preferably 0.5 g and even most preferably more than 0.5
g per liter of
the compound of interest. The production of the compound of interest can be
determined
by a specific assay. Preferably, the filamentous fungal host cell of the
present invention is
an Aspergillus, Trichoderma, Fusarium, Chrysosporum or Penicillium host cell.
More
preferably the filamentous fungal host cell is an Aspergillus niger,
Aspergillus oryzae,
Aspergillus sojae, Aspergillus terreus, Chrysosporum lucknowense, Trichoderma
reesei
or Penicillium chrysogenum host cell. A most preferred Aspergillus niger host
cell is
CBS513.88 or derivatives thereof.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
44
Alternatively and according to another preferred embodiment, when the
polypeptide is an enzyme involved in the production of a given metabolite such
as (beta-
lactam) antibiotics or carotenoids, the filamentous fungal host cell of the
invention is used
for the production of a given metabolite.
According to a further aspect of the invention, there is provided the use of
any one
of the nucleotide sequences defined in the corresponding section in a method
for
producing a compound of interest, the use of a nucleic acid construct or
expression
vector defined in the corresponding section in a method for producing a
compound of
interest and the use of any one of the filamentous fungal host cells as
defined in the
corresponding section in a method for producing a compound of interest.
Method for producing a nucleotide sequence; calculation of the optimized codon
frequency.
According to a further aspect of this invention, there is provided a method
for
producing the nucleotide sequence of the first aspect of the invention,
comprising the
steps of:
- providing a synonymous nucleotide coding sequence with optimized codon
frequency as defined in the first aspect of the invention, and optionally
- operably linking said synonymous nucleotide coding sequence to the control
sequences as defined the first aspect of the invention.
To provide a synonymous nucleotide coding sequence with optimized coding
frequency, the optimized coding frequency can be calculated by the method
provided by
the invention. This method is outlined below.
For the amino acids, hereafter called as group 1 amino acids (AA), there is
only
one possibility. Group 1 consists of methionine that is always encoded by ATG
and
tryptophane that is always encoded by TGG.
The amino acids, hereafter called as group 2 AA, are subject to optimization
according to the extreme frequency of 0% or 100%, the strategy is clear. All
codons for a
group 2 AA are specifically changed into the codons listed below. More
specifically:
- cysteine is always encoded by TGC;
- phenylalanine by TTC;
- histidine by CAC;
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
- lysine by AAG,
- asparagine by AAC;
- glutamine by CAG;
- tyrosine by TAC.
5 All other AA, hereafter called group 3 AA, can be encoded by several codons
as
indicated in Table 1; each codon being present in a preferred codon frequency:
- alanine is encoded by GCT, GCC, GCA, or GCG;
- aspartate by GAT, GAC;
- glutamate by GAA, GAG;
10 - glycine by GGT, GGC, GGA, GGG;
- isoleucine by ATT, ATC, ATA;
- leucine by TTA, TTG, CTT, CTC, CTA, CTG;
- proline by CCT, CCC, CCA, CCG;
- arginine by CGT, CGC, CGA, CGG, AGA, AGG;
15 - serine by TCT, TCC, TCA, TCG, AGT, AGC;
- threonine by ACT, ACC, ACA, ACG;
- valine by GTT, GTC, GTA, GTG.
The following rules apply for calculation of the optimized codon frequency for
group 3 AA in a given coding sequence:
20 For the group 3 AA and their different corresponding codons, the
calculation of the
optimal occurrence of each possible codon within a given coding sequence is
preferably
performed according to the following methodology:
i. sum for each of the respective group 3 AA, the total number of residues
encoded in the given sequence,
25 ii. for each AA and codon encoding that AA, multiply the total number for
that
AA by the optimal codon distribution in Table 1, resulting in a raw codon
distribution, which generally may contain decimal numbers,
iii. round off the values of the raw codon distribution (ii), by removing the
digits, resulting in a rounded off codon distribution,
30 iv. sum for each of the AA, the total number of AA represented in the
rounded
off codon distribution (iii),
v. calculate the total missing number of residues for each of the respective
AA in the rounded off codon distribution, by subtracting the total number of
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
46
residues encoded in the given sequence (i) with the total number of AA
represented in the rounded off codon distribution (iv)
vi. calculate for each codon, the decimal difference between the raw codon
distribution (ii) and the rounded off codon distribution (iii) by subtraction
vii. multiply for each codon, the decimal difference (vi) and the optimal
codon
distribution in table 1, giving a weight value for each codon,
viii. for each of the respective AA, select for the amount of missing residues
(v), the respective amount of codons that have the highest weight value
(vii),
ix. the calculation of the final optimal codon distribution within a given
sequence encoding a polypeptide is calculated by summing the rounded
off codon distribution (iii) and the selected amount of missing residues
(viii) for each codon.
Subsequently, for codons of which the total number in a given sequence is
higher
than in the calculated final optimal codon distribution, a selection is made
for substitution
into a different corresponding codon as calculated. Also for codons that
should be
increased in frequency, a selection is made from the other different
corresponding codon
candidates that should be decreased in frequency (see example 1). In another
preferred
method, one might consider using a computer algorithm for selection and
calculation of
codon replacements in a given nucleotide sequence. In another preferred
embodiment,
the selection and calculation of codon replacements may be done according to
the
calculated codon frequency and criteria for secondary structures and other
features like
inclusion of certain RNA-tags or restriction sites, and avoiding certain
nucleotide
sequences. "Secondary structure" refers to regions of a nucleic acid sequence
that,
when single stranded, have a tendency to form double-stranded hairpin
structures or
loops. Such structures may impede transcription and translation. In WO
01/55342
possible ways are provided how to evaluate nucleic acids for their likeliness
to form
secondary structures. Several software programs can predict secondary
structures. In a
preferred embodiment the secondary structure is determined by the nearest-
neighbor
method. A description of this method is described by Freier et al (Proc Natl
Acad Sci USA
1986, 83, 9373-9377), and uses the energy parameters which refer to RNA:RNA
secondary structure. The application of this method can be done in the Clone
Manager 7
program (Sci. Ed. Central: Scientific & Educational software, version 7.02).
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
47
According to another preferred method, one applies the optimized codon
frequency
according to Table 1 to a specific part of the coding sequence only. In a more
preferred
embodiment of the invention, the substitution of codons in a given nucleotide
sequence is
performed after doing a random selection of candidates for replacement, and a
random
selection of new corresponding codon candidates, according to the final
optimal codon
distribution.
According to another preferred method, one applies the calculated optimal
codon
distribution based on an amino acid sequence only. The amino acid sequence is
back-
translated into a nucleotide sequence by an appropriate choice of codons
according to
the calculated optimal codon distribution into a modified coding sequence with
optimized
codon frequency (example 2). After design of the modified coding sequence, it
might be
checked for secondary structure features, AT-rich stretches and unwanted
restriction
sites. In case one observes such aspects, a person skilled in the art knows
how to
interchange or replace specific codons of the modified coding sequence to
circumvent
the specific issue without changing the encoded polypeptide. In a preferred
embodiment,
this can be done by a computer algorithm taking into account specific criteria
for
secondary structure, avoiding AT-rich regions, avoiding GC-rich regions,
introduction of
restriction sites, etc. In another embodiment, the back-translation is done by
a random
choice of position for each codon that needs to be placed in the nucleotide
sequence.
To provide the nucleotide sequence with the desired modifications, general
molecular biological methods can be applied. These techniques for modifying
nucleotide
sequences utilizing cloning methods are well known in the art. Such methods
include
e.g.: random or directed mutagenesis, DNA shuffling methods, DNA reassembly
methods, gene synthesis, and other means known to one skilled in the art (see
for
example Young and Dong, (2004), Nucleic Acids Research 32, (7) electronic
access
htt :i/nar.ou 'ournals.or /c i/re rint%32/7/e59 or Gupta et al. (1968), Proc.
Natl. Acad. Sci
USA, 60: 1338-1344; Scarpulla et al. (1982), Anal. Biochem. 121: 356-365;
Stemmer et
al. (1995), Gene 164: 49-53).
According to yet another preferred embodiment, there is provided a method for
producing the nucleotide sequence of the second aspect of the invention by
providing a
nucleotide sequence with a translational initiator sequence according to the
second
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
48
aspect of the invention. The techniques for modifying nucleic acid sequences
utilizing
cloning methods are well known in the art.
According to a yet another preferred embodiment, there is provided a method
for
producing a nucleotide sequence comprising a synonymous nucleotide coding
sequence
displaying the combined features of the first and second aspect of the
invention by:
- providing the synonymous nucleotide coding sequence with optimized codon
frequency as defined in the first aspect of the invention using the method
described above,
- providing the nucleotide sequence with a translational initiator sequence
according to the second aspect of the invention using the method described
above, and optionally
- operably linking said synonymous nucleotide coding sequence to the control
sequences as defined the first aspect of the invention.
The present invention is further described by the following examples, which
should not be construed as limiting the scope of the invention.
Examples
Experimental information
Strains
WT 1: This A. niger strain is used as a wild-type strain. This strain is
deposited at the
CBS Institute under the deposit number CBS 513.88.
WT 2: This A. niger strain is a WT 1 strain comprising a deletion of the gene
encoding
glucoamylase (glaA). WT 2 was constructed by using the "MARKER-GENE FREE"
approach as described in EP 0 635 574 B1. In this patent it is extensively
described how
to delete glaA specific DNA sequences in the genome of CBS 513.88. The
procedure
resulted in a MARKER-GENE FREE ?glaA recombinant A. niger CBS 513.88 strain,
possessing finally no foreign DNA sequences at all.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
49
WT 3: This A. niger strain is a WT 2 strain comprising a mutation which
results in an
oxalate deficient A. nigerstrain. WT 3 was constructed by using the method as
described
in EP1 590444. In this patent application, it is extensively described how to
screen for an
oxalate deficient A. nigerstrain. Strain WT3 was constructed according to the
methods of
examples 1 and 2 of EP1590444, strain WT 3 is mutant strain 22 of EP1590444
(designated FINALin EP1590444).
A. niger shake flask fermentations
A. niger strains were pre-cultured in 20 ml pre-culture medium as described in
the
Examples: 'A. niger shake flask fermentations" section of W099/32617. After
overnight
growth, 10 ml of this culture was transferred to fermentation medium 1(FM1)
for alpha-
amylase fermentations and fermentation medium 2(FM2) for phospholipase Al
fermentations. Fermentation is performed in 500 ml flasks with baffle with 100
ml
fermentation broth at 34 C and 170 rpm for the number of days indicated,
generally as
described in W099/32617.
This FM1 medium contains per liter: 70 g glucose, 25 g Caseinhydrolysate, 12.5
g Yeast
extract, 1 g KH2PO4, 2 g K2S04, 0.5 g MgS04.7H2O, 0.03 g ZnC12, 0.02 g CaC12,
0.01
g MnS04.4H20, 0.3 g FeS04.7H20, 10 ml Pen-Strep (Invitrogen, cat. nr. 10378-
016),
adjusted to pH 5.6 with 4 NH2SO4.
The FM2 medium contains per liter: 82.5 g Glucose.1 H20, 25 g Maldex 15 (Boom
Meppel, Netherlands), 2 g Citric acid, 4.5 g NaH2PO4.1 H20, 9 g KH2PO4, 15 g
(NH4)2SO4, 0.02 g ZnC12, 0.1 g MnS04.1 H20, 0.015 g CuS04.5H20, 0.015 g
CoC12.6H20, 1 g MgS04.7H2O, 0.1 g CaC12.2H2O, 0.3 g FeS04.7H20, 30 g MES (2-
[N-Morpholino]ethanesulfonic acid), pH=6.
PLA1 phospholipase activity
To determine phospholipase PLA1 activity (plal) in A. niger culture broth
spectrophotometrically, an artificial substrate is used: 1,2-dithiodioctanoyl
phophatidylcholine (diC8, substrate). plal hydrolyses the sulphide bond at the
Al
position, dissociating thio-octanoic acid. Thio-octano'ic acid reacts with 4,4
dithiopyridine
(color reagent, 4-DTDP), forming 4-thiopyridone. 4-Thiopyridone is in
tautomeric
equilibrium with 4-mercaptopyridine, which absorbs radiation having a
wavelength of 334
nm. The extinction change at that wavelength is measured. One unit is the
amount of
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
enzyme that liberates of 1 nmol thio-octanoic acid from 1,2-dithiodioctanoyl
phosphatidylcholine per minute at 379C and pH 4Ø
The substrate solution is prepared by dissolving 1 g diC8 crystals per 66 ml
5 ethanol and add 264 ml acetate buffer. The acetate buffer comprises 0.1 M
Acetate buffer
pH 3.85 containing 0.2% Triton-X100. The color reagent is a 11 mM 4,4-
dithiodipyridine
solution. It was prepared by weighting 5,0 mg 4,4-dithiodipyridine in a 2 ml
Eppendorf
sample cup and dissolving in 1.00 ml ethanol. 1.00 ml of milli-Q water was
added.
10 Fungal alpha-amylase activity
To determine the alpha-amylase activity in A. nigerculture broth, the Megazyme
cereal alpha-amylase kit is used (Megazyme, CERALPHA alpha amylase assay kit,
catalogus. ref. K-CERA, year 2000-2001), according protocol of the supplier.
The
measured activity is based on hydrolysis of non-reducing-endblocked p-
nitrophenyl
15 maltoheptaoside in the presence of excess glucoamylase and a-glucosidase.
The
amount of formed p-nitrophenol is a measure for alpha-amylase activity present
in a
sample.
Example 1. Construction of an Aspergillus expression construct for the pial
gene
20 encoding A. oryzae phospholipase Al and the amyA gene encoding A. ni_ger
alpha-
amylase
The DNA sequence of the plal gene encoding the phospholipase Al protein was
disclosed in JP 1998155493-A/1 and also can be retrieved from EMBL Nucleotide
Sequence Database (http://www.ebi.ac.uk/embl/index.html) under accession
number
25 E16314. The genomic sequence of the native A. oryzae plal gene is shown as
SEQ ID
NO: 1. The corresponding coding sequence of plal is shown as SEQ ID NO: 2. The
translated sequence of SEQ ID NO: 2 is assigned as the SEQ ID NO: 3,
representing the
A. oryzae phospholipase Al.
The DNA sequence of the amyA gene encoding the alpha-amylase protein was
disclosed
30 in Curr Genet. 1990 Mar;17(3):203-212 (Cloning, characterization, and
expression of two
alpha-amylase genes from Aspergillus nigervar. awamori by Korman DR, Bayliss
FT,
Barnett CC, Carmona CL, Kodama KH, Royer TJ, Thompson SA, Ward M, Wilson LJ,
Berka RM) and also can be retrieved from EMBL Nucleotide Sequence Database
(http://www.ebi.ac.uk/embl/index.html) under accession number AB1 09452. The
genomic
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
51
sequence of the native A. niger amyA gene is shown as SEQ ID NO. 28. The
corresponding coding or cDNA sequence of amyA is shown as SEQ ID NO. 29. The
translated sequence of SEQ ID NO. 29 is assigned as the SEQ ID NO. 30,
representing
the A. nigeralpha-amylase protein.
For expression analysis in Aspergillus species of plal constructs, a fusion of
the
genomic plal gene and the A. nigerglucoamylase promoter was made at the
translation
start site accompanied by the introduction of cloning sites. To do so, a PCR
was
performed for amplification of the genomic plal gene using the
oligonucleotides identified
as SEQ ID NO 4 and SEQ ID NO 5 and the plal gene construct cloned in pGBFIN1
1,
described in WO 04/070022, as template, generating a 1.1 kb fragment
identified as
fragment A. Additionally, a SnaBI cloning site was introduced. A second PCR
was
performed using the oligonucleotides identified as SEQ ID NO 6 and SEQ ID NO 7
and
the pGBFIN-23 vector (described in W099/32617) as template, generating a 0.4
kb glaA
promoter fragment identified as fragment B. Both resulting fragments, A and B,
were
fused by sequence overlap extension (SOE-PCR, as described in Gene. 1989 Apr
15;77(1):51-9. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR "Site-directed
mutagenesis by overlap extension using the polymerase chain reaction") using
PCR,
oligonucleotides identified as SEQ ID NO 5 and SEQ ID ND 6 and fragments A and
B
described above; generating a 1.4 kb fragment C. This fragment C, comprising
the
genomic plal gene and part of the glaA promoter was digested with Sfil and
SnaBI and
introduced in a Sfil and Nrul digested pGBFIN-30 vector (Figure 1), generating
pGBFINPLA 1 a(Fig. 2). The sequence of the introduced and digested PCR
fragment C
was confirmed by sequence analysis and its sequence is given in SEQ ID NO 8.
For expression analysis in Aspergillus species of A. niger amyA constructs, a
fragment
containing the genomic amyA promoter and the amyA cDNA sequence was amplified
and fused using PCR in a similar strategy as described above. Appropriate
restriction
sites were introduced at both ends to allow cloning in an expression vector.
At the 5'-end
an Xhol site was introduced and at the 3'-end a Pacl site. This fragment
comprising the
alpha-amylase promoter and cDNA sequence was digested with Xhol and Pacl and
introduced in an Xhol and Pacl digested pGBFIN-12 vector (construction and
layout
described in W099/32617), generating pGBFINFUA-1 (Fig. 4). The sequence of the
introduced PCR fragment was confirmed by sequence analysis and its sequence is
presented in SEQ ID NO. 31.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
52
Example 2: Use of a method of the invention for construction of improved DNA
sequences for improving production of the phospholipase Al enzyme of
Asaeraillus orvzae in A. niaer.
2.1. Improvement of the codon frequency or codon usage for the A. oryzae
phospholipase Al coding sequence for expression in A. ni_ger
The method of the invention was below applied to the improvement of codon use
of the PLA1 gene of A. oryzae. This method can be applied the same way for the
improvement of codon use of any nucleotide sequence. The nucleotide coding
sequence
of plal is shown as SEQ ID NO:2.
The codon use of the native A. oryzae gene encoding PLA1 and the synthetic
optimized variant are given in Table 2 below. For the native and optimized
synthetic plal
gene, the exact numbers for each codon are given as well as the distribution
per amino
acid. Additionally, the third column provides the proposed optimal
distribution, which is the
target for optimization.
For the group 1 amino acids, there is only one possibility. Group 1 consists
of
methionine that is always encoded by ATG and tryptophane ihat is always
encoded by
TGG.
The group 2 amino acids are subject to optimization according to the extreme
frequency of 0% or 100%, the strategy is clear. All codons for a group 2 AA
are
specifically changed into the optimal variant of the two possible codons. More
specifically
for cysteine, a codon, TGT is replaced by TGC; for phenylalanine, TTT by TTC;
for
histidine, CAT by CAC; for lysine, AAA by AAG, for asparagine, AAT by AAC; for
glutamine, CAA by CAG; for tyrosine, TAT by TAC.
The group 3 amino acids can be encoded by several codons as indicated in Table
1; each codon being present in a preferred codon frequency: for alanine GCT,
GCC,
GCA, GCG; for aspartate, GAT, GAC; for glutamate, GAA, GAG; for glycine, GGT,
GGC,
GGA, GGG; for isoleucine, ATT, ATC, ATA; for leucine, TTA, TTG, CTT, CTC, CTA,
CTG;
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
53
for proline, CCT, CCC, CCA, CCG; for arginine, CGT, CGC, CGA, CGG, AGA, AGG;
for
serine, TCT, TCC, TCA, TCG, AGT, AGC; for threonine, ACT, ACC, ACA, ACG; for
valine, GTT, GTC, GTA, GTG, are optimized according the following methodology:
For the group 3 amino acids (AA) and their encoding codons, the calculation of
the optimal occurrence of each possible codon within a given coding sequence
is
performed according to the following methodology:
i. sum for each of the respective group 3 AA, the total number of residues
encoded
in the given sequence, see column Al (Table 3),
ii. for each AA and codon encoding that AA, multiply the total number for that
AA by
the optimal codon distribution in Table 1, resulting in a raw codon
distribution,
which generally may contain decimal numbers, see column A2 (Table 4),
iii. round off the values of the raw codon distribution (ii), by removing the
digits,
resulting in a rounded off codon distribution, see column A3 (Table 4),
iv. sum for each of the AA, the total number of AA represented in the rounded
off
codon distribution (iii), see column A4 (Table 3),
v. calculate the total missing number of residues for each of the respective
AA in the
rounded off codon distribution, by subtracting the total number of residues
encoded in the given sequence (i) with the total number of AA represented in
the
rounded off codon distribution (iv), see column A5 (Table 3),
vi. calculate for each codon, the decimal difference between the raw codon
distribution (ii) and the rounded off codon distribution (iii) by subtraction,
see
column A6 (Table 4),
vii. multiply for each codon, the decimal difference (vi) and the optimal
codon
distribution in table 1, giving a weight value for each codon, see column A7
(Table
4),
viii. for each of the respective AA, select for the amount of missing residues
(v), the
respective amount of codons that have the highest weight value (vii), see
column
A8 (Table 4),
ix. the calculation of the final optimal codon distribution within a given
sequence
encoding a polypeptide is calculated by summing the rounded off codon
distribution (iii) and the selected amount of missing residues (viii) for each
codon, see column A9 (Table 4).
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
54
Table 2 Codon optirnization for PLA1.
AA Codon Optimal PLA1 PLA1 PLA1 PLA1
codon w.t. w.t. optimized optimized
distribution [# [% [# codons] [% codons
[~~o] codons] codons / AA]
/AA]
A Ala GCT 38 10 28.6 14 40.0
Ala GCC 51 12 34.3 18 51.4
Ala GCA 0 9 25.7 0 0.0
Ala GCG 11 4 11.4 3 8.6
C Cys_TGT 0 4 66.7 0 0.0
Cys_TGC 100 2 33.3 6 100.0
D Asp_GAT 36 14 73.7 7 36.8
Asp_GAC 64 5 26.3 12 63.2
E Glu GAA 26 7 46.7 4 26.7
Glu GAG 74 8 53.3 11 73.3
F Phe TTT 0 5 55.6 0 0.0
Phe TTC 100 4 44.4 9 100.0
G Gly_GGT 49 6 26.1 12 52.2
Gly_GGC 35 7 30.4 8 34.8
Gly_GGA 16 5 21.7 3 13.0
Gly_GGG 0 5 21.7 0 0.0
H His CAT 0 4 50.0 0 0.0
His CAC 100 4 50.0 8 100.0
I Ile ATT 27 3 33.3 2 22.2
Ile ATC 73 6 66.7 7 77.8
IIe ATA 0 0 0.0 0 0.0
K Lys_AAA 0 2 33.3 0 0.0
Lys_AAG 100 4 66.7 6 100.0
L Leu TTA 0 1 2.9 0 0.0
Leu TTG 13 9 26.5 4 11.8
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
Leu CTT 17 2 5.9 6 17.6
Leu CTC 38 8 23.5 13 38.2
Leu CTA 0 2 5.9 0 0.0
Leu CTG 32 12 35.3 11 32.4
M Met ATG 100 1 100.0 1 100.0
N Asn AAT 0 5 27.8 0 0.0
Asn AAC 100 13 72.2 18 100.0
P Pro CCT 36 3 37.5 3 37.5
Pro CCC 64 2 25.0 5 62.5
Pro CCA 0 2 25.0 0 0.0
Pro CCG 0 1 12.5 0 0.0
Q Gln CAA 0 3 60.0 0 0.0
Gln CAG 100 2 40.0 5 100.0
R Arg_CGT 49 0 0.0 4 50.0
Arg_CGC 51 2 25.0 4 50.0
Arg_CGA 0 2 25.0 0 0.0
Arg_CGG 0 3 37.5 0 0.0
Arg_AGA 0 1 12.5 0 0.0
Arg_AGG 0 0 0.0 0 0.0
S Ser TCT 21 5 15.2 7 21.2
Ser TCC 44 7 21.2 15 45.5
Ser TCA 0 5 15.2 0 0.0
Ser TCG 14 2 6.1 4 12.1
Ser AGT 0 4 12.1 0 0.0
Ser AGC 21 10 30.3 7 21.2
T Thr ACT 30 7 29.2 7 29.2
Thr ACC 70 8 33.3 17 70.8
Thr ACA 0 2 8.3 0 0.0
Thr ACG 0 7 29.2 0 0.0
V Val GTT 27 5 33.3 4 26.7
Val GTC 54 4 26.7 8 53.3
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
56
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
Val GTA 0 1 6.7 0 0.0
Val GTG 19 5 33.3 3 20.0
W Trp_TGG 100 4 100.0 4 100.0
Y Tyr_TAT 0 6 40.0 0 0.0
Tyr_TAC 100 9 60.0 15 100.0
Table 3
AA(i) i Al A4 A5
Ala 1 35 33 2
Asp 2 19 18
Glu 3 15 14
Gly 4 23 22
Ile 5 9 8
Leu 6 34 31 3
Pro 7 8 7
Arg 8 8 7
Ser 9 33 30 3
Thr 10 24 23
Val 11 15 14
Table 4
Codon A2 A3 A6 A7 A8 A9
Ala_GCT 13.3 13 0.3 0.114 1 14
Ala_GCC 17.85 17 0.85 0.434 1 18
Ala GCA 0 0 0 0.000 0 0
Ala GCG 3.85 3 0.85 0.094 0 3
Asp_GAT 6.84 6 0.84 0.302 1 7
Asp_GAC 12.16 12 0.16 0.102 0 12
Glu GAA 3.9 3 0.9 0.234 1 4
Glu_GAG 11.1 ll 0.1 0.074 0 11
Gly_GGT 11.27 ll 0.27 0.132 1 12
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
57
Gly_GGC 8.05 8 0.05 0.018 0 8
Gly_GGA 3.68 3 0.68 0.109 0 3
Gly_GGG 0 0 0 0.000 0 0
Ile_ATT 2.43 2 0.43 0.116 0 2
Ile ATC 6.57 6 0.57 0.416 1 7
Ile ATA 0 0 0 0.000 0 0
Leu TTA 0 0 0 0.000 0 0
Leu TTG 4.42 4 0.42 0.055 0 4
Leu CTT 5.78 5 0.78 0.133 1 6
Leu CTC 12.92 12 0.92 0.350 1 13
Leu_CTA 0 0 0 0.000 0 0
Leu_CTG 10.88 10 0.88 0.282 1 11
Pro CCT 2.88 2 0.88 0.317 1 3
Pro CCC 5.12 5 0.12 0.077 0 5
Pro_CCA 0 0 0 0.000 0 0
Pro_CCG 0 0 0 0.000 0 0
Arg_CGT 3.92 3 0.92 0.451 1 4
Arg_CGC 4.08 4 0.08 0.041 0 4
Arg_CGA 0 0 0 0.000 0 0
Arg_CGG 0 0 0 0.000 0 0
Arg_AGA 0 0 0 0.000 0 0
Arg_AGG 0 0 0 0.000 0 0
Ser TCT 6.93 6 0.93 0.195 1 7
Ser TCC 14.52 14 0.52 0.229 1 15
Ser_TCA 0 0 0 0.000 0 0
Ser TCG 4.62 4 0.62 0.087 0 4
Ser_AGT 0 0 0 0.000 0 0
Ser_AGC 6.93 6 0.93 0.195 1 7
Thr ACT 7.2 7 0.2 0.060 0 7
Thr_ACC 16.8 16 0.8 0.560 1 17
Thr_ACA 0 0 0 0.000 0 0
Thr_ACG 0 0 0 0.000 0 0
Val GTT 4.05 4 0.05 0.014 0 4
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
58
Val_GTC 8.1 8 0.1 0.054 0 8
Val_GTA 0 0 0 0.000 0 0
Val GTG 2.85 2 0.85 0.162 1 3
Subsequently, for codons of which the total number in the plal coding sequence
was higher than the calculated final codon distribution, a random selection
was made for
substitution into a different corresponding codon as calculated. Also for
codons that
should be increased in the plal coding sequence, a random selection was made
from
the other different corresponding codon candidates that should be decreased in
frequency.
This resulted in a modified coding sequence (or synonymous coding sequence or
optimized synthetic sequence) as depicted in Table 2. The optimized synthetic
plal
sequence, resulting from the process described above, is shown in Figure 6.
Here an
alignment of the modified coding sequence of the invention with the native and
genomic
plal sequence can be found. In this modified coding sequence, the three
introns of the
native sequence were placed at their original position (as indicated in SEQ ID
NO 1),
resulting in the optimized synthetic sequence as shown in the SEQ ID NO 11.
Secondary
structures in the modified coding sequence were checked using the Clone
Manager 7
program (Sci. Ed. Central: Scientific & Educational software, version 7.02)
for possible
occurrence of harmful secondary structures.
2.2: Choice of a modified translational termination sequence
The native plal gene encoding A. oryzae phospholipase Al contains a'TAG' stop
codon followed by TACGTA of the introduced SnaBl restriction site. In a number
of
synthetic constructs, the 5'-TAGT-3' translational termination sequence is
replaced by
TAAA followed by the same TACGTA of the SnaBl restriction site. This
replacement has
been done in the sequences of SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ
ID
NO. 14, SEQ ID NO. 35. As a result of this, the expression constructs
pGBFINPLA-ld,
pGBFINPLA-le, pGBFINPLA 1f, pGBFINPLA-lg and pGBFINPLA-lh have a modified
translational termination sequence according to the invention.
2.3: Choice of a modified translational initiation seguences
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
59
The strong glaA promotor is applied for over-expression of enzymes in A. niger
using the pGBFIN expression constructs. The translational initiation sequence
including
ATG start codon of PglaA is 5'-CACCTCAGCA ATG-3'. The translational initiation
sequence of PglaA has been modified into 5'-CACCGTCAAA-3' or 5'-CGCAGTCAAG-3'.
This results in a glucoamylase promoter sequence downstream of the EcoRl site
as can
be identified in SEQ ID NO 25 and 26, respectively. This replacement was
performed in
the sequences of SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 12, SEQ ID NO. 13 and
SEQ ID NO. 14. As a result of this, the expression constructs pGBFINPLA-lb,
pGBFINPLA 1c, pGBFINPLA-le, pGBFINPLA-lf and pGBFINPLA-lg have a modified
translational initiation sequence according to the invention. The
translational initiator
sequence as described in US 6,461,837 B1 has been tested in the sequence of
SEQ ID
NO. 35, resulting in the expression constructs pGBFINPLA-1 h.
2.4: Choice of modified translational initiation coding sequence
Modification of the translational initiation coding sequence can be combined
with
the codon optimization and/or improvement of the translational initiation
coding sequence.
Substitution of the second codon in the coding sequence is clear because only
one
codon is optimal, i.e., the codon is replaced by GCT coding alanine. The third
codon has
4 options: TCC; CCC; ACC; GCC, encoding serine, proline, threonine, and
arginine,
respectively. TCC was selected. The fourth codon can either be TTC for
phenylalanine,
TTC for serine, CTC for leucine, or CCC for proline. TTC was selected. This
leads to 5'-
ATGGCTTCCTTC-3' as modified translational initiation coding sequence including
start
codon. This results in a glucoamylase promoter sequence downstream of the
EcoRl site
and with translational initiation coding sequence as can be identified in SEQ
ID NO 27.
This modified sequence is used in SEQ ID NO. 14. As a result of this, the
expression
construct pGBFINPLA-lg has a modified translational initiation coding sequence
according to the invention.
2.5: Combination of at least one of the modifications made in 2.1 to 2.4
Expression of the nucleotide sequence coding for the polypeptide to be
produced
may be improved by optimizing the codon usage, and/or the consensus
translational
initiator coding sequence and/or control DNA sequences comprising a consensus
translational initiator sequence and/or optimal translational termination
sequence. A
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
series of 8 constructs (Table 5) was analysed to test a number of embodiments
of the
invention.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
61
Table 5: Several improved expression constructs using at least one of the
modified
sequences. Translational initiator sequence variant 1: CACCGTCAAA; variant 2:
CGCAGTCAAG.
SEQ ID NO Translational Translational initiation Codon usage Translation
termination
initiation sequence coding sequence sequence
8 w.t. w.t. w.t. w.t.
9 variant 1 w.t. w.t. w.t.
variant 2 w.t. w.t. w.t.
11 w.t. w.t. modified w.t.
12 variant 1 w.t. modified Modified (TAA ATA)
13 variant 2 w.t. modified Modified (TAA ATA)
14 variant 1 Optimized modified Modified (TAA ATA)
(ATGGCTTCCTTC)
35 US 6,461,837 B1 w.t. modified Modified (TAA ATA)
5
Example 3: Use of a method of the invention for construction of improved DNA
sequences for improving production of the alpha-amylase enzyme in A. ni_ger.
10 3.1. Improvement of the codon frequency or codon usage for the alpha-
amylase
coding sequence amyA for expression in A. ni_ger
The method of the invention is below applied to the improvement of codon use
of the
amyA gene of A. niger. This method can be applied the same way for the
improvement of
codon use of any nucleotide sequence. The nucleotide coding sequence of the
native
amyA is shown as SEQ ID NO. 29.
X. The codon use of the native amyA gene of A. niger and the synthetic
optimized variant are given in Table 6 below. For the native and optimized
synthetic amyA gene, the exact numbers for each codon are given as well as
the distribution per amino acid. Additionally, the third column provides the
proposed optimal distribution, which is the target for optimization.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
62
Table 6 Codon optimization for amyA.
AA Codon Optimal amyA amyA amyA amyA
codon w.t. w.t. optimized optimized
distribution [# [% [# codons] [% codons
[%] codons] codons / AA]
/AA]
A Ala GCT 38 5 11.9 16 38.1
Ala GCC 51 15 35.7 21 50.0
Ala GCA 0 12 28.6 0 0.0
Ala GCG 11 10 23.8 5 11.9
C Cys_TGT 0 7 77.8 0 0.0
Cys_TGC 100 2 22.2 9 100.0
D Asp_GAT 36 20 47.6 15 35.7
Asp_GAC 64 22 52.4 27 64.3
E Glu GAA 26 5 41.7 3 25.0
Glu GAG 74 7 58.3 9 75.0
F Phe TTT 0 3 20.0 0 0.0
Phe TTC 100 12 80.0 15 100.0
G Gly_GGT 49 10 23.3 21 48.8
Gly_GGC 35 18 41.9 15 34.9
Gly_GGA 16 10 23.3 7 16.3
Gly_GGG 0 5 11.6 0 0.0
H His CAT 0 3 42.9 0 0.0
His CAC 100 4 57.1 7 100.0
I Ile ATT 27 7 25.0 7 25.0
Ile ATC 73 19 67.9 21 75.0
Ile ATA 0 2 7.1 0 0.0
K Lys_AAA 0 7 35.0 0 0.0
Lys_AAG 100 13 65.0 20 100.0
L Leu TTA 0 1 2.7 0 0.0
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
63
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
Leu TTG 13 10 27.0 5 13.5
Leu CTT 17 4 10.8 6 16.2
Leu CTC 38 13 35.1 14 37.8
Leu CTA 0 3 8.1 0 0.0
Leu CTG 32 6 16.2 12 32.4
M Met ATG 100 10 100.0 10 100.0
N Asn AAT 0 3 11.5 0 0.0
Asn AAC 100 23 88.5 26 100.0
P Pro CCT 36 6 27.3 8 36.4
Pro CCC 64 8 36.4 14 63.6
Pro CCA 0 3 13.6 0 0.0
Pro CCG 0 5 22.7 0 0.0
Q Gln CAA 0 5 25.0 0 0.0
Gln CAG 100 15 75.0 20 100.0
R Arg_CGT 49 1 10.0 5 50.0
Arg_CGC 51 2 20.0 5 50.0
Arg_CGA 0 2 20.0 0 0.0
Arg_CGG 0 2 20.0 0 0.0
Arg_AGA 0 0 0.0 0 0.0
Arg_AGG 0 3 8.1 0 0.0
S Ser TCT 21 4 10.8 8 21.6
Ser TCC 44 9 24.3 16 43.2
Ser TCA 0 4 10.8 0 0.0
Ser TCG 14 10 27.0 5 13.5
Ser AGT 0 4 10.8 0 0.0
Ser AGC 21 6 16.2 8 21.6
T Thr ACT 30 9 22.5 12 30.0
Thr ACC 70 13 32.5 28 70.0
Thr ACA 0 10 25.0 0 0.0
Thr ACG 0 8 20.0 0 0.0
V Val GTT 27 5 16.1 8 25.8
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
64
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . .
Val GTC 54 12 38.7 17 54.8
Val GTA 0 4 12.9 0 0.0
Val GTG 19 10 32.3 6 19.4
W Trp_TGG 100 12 100.0 12 100.0
Y Tyr_TAT 0 11 31.4 0 0.0
Tyr_TAC 100 24 68.6 35 100.0
Subsequently, a completely new nucleotide coding sequence is created by
random distribution of the proposed number of synonymous codons (Table 6) for
each
amino acid in the original amyA peptide.
The native amyA gene contains a'TGA' stop codon. In all amyA constructs
made, the 5'-TGA-3' translational termination sequence was replaced by 5'-TAAA-
3'
followed by the 5'-TTAATTAA-3' of the Pacl restriction site.
This resulted in a modified coding sequence (or synonymous coding sequence or
optimized synthetic sequence) as depicted in Table 6. The optimized synthetic
amyA
sequence, resulting from the process described above, is indicated in SEQ ID
NO 32.
Secondary structures in the modified coding sequence was checked using the
Clone
Manager 7 program (Sci. Ed. Central: Scientific & Educational software,
version 7.02) for
possible occurrence of harmful secondary structures.
3.2: Choice of a modified translational initiation seguences
In this example, the strong amyA promotor is applied for over-expression of
the
alpha amylase enzyme in A. niger using pGBFIN-based expression constructs. The
translational initiation sequence including ATG start codon of PamyA is 5'-
GGCATTTATG
ATG-3' or 5'-GAAGGCATTT ATG-3', dependent on which ATG is selected as start
codon.
The translational initiation sequence of PamyA has been modified into 5'-
CACCGTCAAA
ATG-3'. This replacement has been done in the sequences of SEQ ID NO. 33 and
SEQ
ID NO. 34. As a result of this, the expression constructs pGBFINFUA-2 and
pGBFINFUA-
3, have a modified translational initiation sequence according to the
invention.
3.3: Combination of at least one of the modifications made in 3.1 and 3.2
Expression of the sequence coding for the polypeptide to be produced may be
improved by optimizing the codon usage and/or control DNA sequences comprising
a
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
consensus translational initiator sequence and/or optimal translational
termination
sequence. A series of 3 constructs (Table 7) was constructed to test a number
of
embodiments of the invention.
5 Table 7: Overview of improved expression constructs using at least one of
the modified
sequences.
SEQ ID NO Translational initiation Codon usage Translation termination
sequence sequence
31 w.t. w.t. Modified (TAA ATTAA)
33 variant 1(CACCGTCAAA) w.t. Modified (TAA ATTAA)
34 variant 1(CACCGTCAAA) modified Modified (TAA ATTAA)
10 Example 4. Construction of modified expression vectors and testing them in
A.
niaer
4.1. Construction of modified plal expression vectors expressing A. oryzae
phospholipase Al according example 2.1 - 2.5
15 The DNA sequence of the cloned EcoRl - SnaBl fragment of pGBFINPLA 1 a is
shown as SEQ ID NO 8. The DNA sequences of EcoRl fragments comprising variants
for the translational initiation sequence of the glucoamylase promoter are
shown as SEQ
ID NO 9 and SEQ ID NO 10. These modified gene fragments were completely
synthesized and the sequence was confirmed by sequence analysis.
For cloning these modified sequence variants in an expression vector, all
synthetic gene fragments were digested with EcoRl and introduced in the large
fragment
of an EcoRl digested pGBFINPLA 1 a vector (Figure 2), generating variant
expression
vectors of pGBFINPLA-la. After checking for the proper orientation of the
EcoRl
fragment, the variant expression constructs were named pGBFINPLA1b and
pGBFINPLA-lc as described below in Table 8. Figure 3 is also providing a
representative
map for plasmid pGBFINPLA-1 b and pGBFINPLA 1 c.
The DNA sequence of 5 other synthetic sequence variants comprising part of the
glucoamylase promoter, the plal signal sequence, the mature peptide of
phospholipase
Al and the translational termination sequence around the stop codon are shown
as SEQ
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
66
ID NO 11 until SEQ ID NO 14 and SEQ ID NO 35. These 5 modified gene fragments
were completely synthesized by design and synthesis of overlapping
polynucleotides and
subsequent assembly of the double-stranded sequence from a number of
overlapping
polynucleotides. The sequence was confirmed by sequence analysis.
For cloning these modified sequence variants in an expression vector, all
synthetic gene fragments were digested with EcoRl and SnaBI and introduced in
the
large fragment of an EcoRl and Nrul digested pGBFINPLA-la vector (Figure 2),
generating variant expression vectors pGBFINPLA-1d until pGBFINPLA 1 h as
described
below in Table 8. A representative map for the plasmids pGBFINPLA-ld until
pGBFINPLA-1 h is provided in figure 3.
Table 8: Modified expression constructs for plal expression in A. niger
Plasmid name SEQ ID NO Translation start region Codon Translation stop
PGBFINPLA-1 a 8 CACCTCAGCA ATG TTT AGT CTC w.t TAG TAC
PGBFINPLA-1 b 9 CACCGTCAAA ATG TTT AGT CTC w.t TAG TAC
PGBFINPLA-lc 10 CGCAGTCAAG ATG TTT AGT CTC w.t TAG TAC
PGBFINPLA-ld 11 CACCTCAGCA ATG TTC TCT CTC modified Modified
(TAA ATA)
PGBFINPLA-le 12 CACCGTCAAA ATG TTC TCT CTC modified Modified
(TAA ATA)
PGBFINPLA-lf 13 CGCAGTCAAG ATG TTC TCT CTC modified Modified
(TAA ATA)
PGBFINPLA-lg 14 CACCGTCAAA ATG GCT TCC TTC modified Modified
(TAA ATA)
pGBFINPLA-1 h 35 CTCCTTCACC ATG TTC TCT CTC modified Modified
(TAA ATA)
The translated sequences of the plal coding sequences of plasmid pGBFINPLA-
la until pGBFINPLA 1 f and pGBFINPLA 1 h are according the amino acid sequence
as
identified in SEQ ID NO: 3, representing the wild-type A. oryzae phospholipase
Al. The
translated sequence of the plal coding sequence of plasmid pGBFINPLA-lg is
according
the amino acid sequence as identified in SEQ ID NO: 15, representing an A.
oryzae
phospholipase Al with a modified signal sequence.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
67
4.2. Construction of modified amyAexpression vectors expressing A. ni_geralpha-
amylase according example 3.1 - 3.3
The DNA sequence of the Xhol - Pacl fragment of pGBFINFUA-1 (Figure 4) is
shown as SEQ ID NO 31 and comprises the wild-type amyA promoter and wild-type
amyA cDNA sequence with a modified translation stop sequence (TAAA). The DNA
sequence comprising a variant for the translational initiation sequence of the
alpha-
amylase promoter is shown as SEQ ID NO 33. The DNA sequence comprising a
variant
of the translational initiation sequence of the alpha-amylase promoter
combined with a
codon optimized coding sequence for alpha-amylase encoding amyA gene is shown
as
SEQ ID NO 34. These modified gene fragments were completely synthesized in
vitro and
the sequence was confirmed by sequence analysis.
For cloning these modified sequence variants in an expression vector, all
synthetic gene fragments were digested with Xhol and Pacl and introduced in
the large
fragment of an Xhol and Pacl digested pGBFINFUA-1 vector (Figure 4),
generating variant
expression vectors. After checking the integration of the correct fragment,
the variant
expression constructs were named pGBFINFUA-2 and pGBFINFUA-3 as described
below in Table 9.
Table 9: Modified expression constructs for alpha-amylase expression in A.
niger
Plasmid name SEQ ID NO Translation start region Codon Translation stop
pGBFINFUA-1 31 Wild type w.t Modified
(GAAGGCATTT ATG) (TAA ATA)
pGBFINFUA-2 33 Modified w.t Modified
(CACCGTCAAA ATG) (TAA ATA)
pGBFINFUA-3 34 Modified Modified Modified
(CACCGTCAAA ATG) (TAA ATA)
The translated sequences of the amyA coding sequences of plasmid
pGBFINFUA-1 to pGBFINFUA-3 are according to the amino acid sequence as
depicted in
SEQ ID NO: 30, representing the wild-type A. nigeralpha-amylase.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
68
4.3. Expression in A. niger of wild-type and modified expression constructs of
A. oryzae phospholipase Al using the pGBFINPLAr vectors and of A. ni_ger alpha-
amylase using the pGBFINFUPe vectors
The pGBFINPLA- and pGBFINFUA- expression constructs, prepared in the former
paragraph, were introduced in A. niger by transformation as described below
and
according to the strategy depicted in figure 5.
In order to introduce the eight pGBFINPLA- vectors (Table 8) in WT 2 and the
three pGBFINFUA- vectors (Table 9) in WT 3, a transformation and subsequent
selection
of transformants was carried out as described in W098/46772 and W099/32617. In
brief, linear DNA of the pGBFIN constructs was isolated and used to transform
A. niger.
Transformants were selected on acetamide media and colony purified according
standard procedures. Colonies were diagnosed for integration at the glaA locus
and for
copy number using PCR. Five to ten independent transformants of each pGBFIN
construct with similar estimated copy numbers (low copy: 1-2) were selected
and named
using the number of the transforming plasmid, as for example PLA-1 a-1, PLA-1
b-2 and
FUA-1-1, FUA-3-1, respectively.
The selected PLA- and FUA- strains and A. niger WT 2 and WT 3 were used to
perform shake flask experiments in 100 ml of the medium as described above for
each of
the protein products at 34 C and 170 rpm in an incubator shaker using a 500 ml
baffled
shake flask. After 2, 3, 4, 5 and/or 6 days of fermentation, samples were
taken.
In a first step, the plal and amyA over-expression was measured by Northern
blot
analysis of the transformants of A. niger WT 2 and WT 3 and WT2 and WT 3
themselves. The collected mycelium was used for isolation of RNA (as described
in
W099/32617) and Northern blot analysis following the standard procedures of
Northern
blot analysis (Sambrook et al., 1989). For all transformants of the wild-type
plal gene, but
not for WT2 itself, a strong and comparable hybridization signal was detected
for the plal
mRNA level (data not shown). This indicates that the transcriptional control
of the plal
gene by the glucoamylase promoter in all transformed strains of pGBFINPLA-1 a
until
pGBFINPLA 1 c was intact and unchanged compared to the wild-type glaA
promoter.
Additionally, plal over-expression of the plal modified constructs was
measured by
Northern blot analysis of the concerning PLA transformants of A. niger WT 2
and WT2
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
69
itself. For all transformants of the modified synthetic plal genes, but not
for WT2 itself, a
strong and comparable hybridization signal was detected (data not shown). This
indicates that the transcriptional control of the optimized plal genes by the
glucoamylase
promoter in all transformed strains of pGBFINPLA-ld until pGBFINPLA-1 h was
intact and
that the synthetic plal genes were expressed.
In a similar way, the amyA over-expression of the native and modified
constructs
was measured by Northern blot analysis of the concerning FUA transformants of
A. niger
WT 3 and WT3 itself, using a (universal) probe located in the 3'-untranslated
region of the
glucoamylase terminator used in all three expression contructs. For all
transformants of
amyA constructs, a strong and comparable hybridization signal was detected
(data not
shown). This indicates that the transcriptional control of the optimized amyA
genes by the
alpha-amylase promoter in all transformed strains of pGBFINFUA-1 to pGBFINFUA-
3 was
intact and that the synthetic amyA genes were expressed.
The production of phospholipase Al polypeptide was measured in all A. nigerPLA
transformants. As can be seen in Figure 7, a positive effect of the use of a
modified
translation initiation site (variant 1 and variant 2) on phospholipase
production can be
observed using the glucoamylase promoter. Similarly, a positive effect of
modification of
codon usage and the translation stop sequence on phospholipase production was
observed. A summary of the results is shown in Table 10 below. This indicates
clearly
how a single modification or a combination of modifications of the invention,
for example
a modified translation initiation sequence, such as variant 1, 2 or the
variant described in
US6,461,837 Bl, and/or a modified codon usage and/or a modified translation
stop
sequence can be used to improve the yield of production of the phospholipase
Al in
A. niger.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
Table 10. Relative average phospholipase activities compared to wild-type
construct for
modified plal control and coding sequences (as concluded from Figure 7).
5
Pl SEQ Translational Translational Optimized Translational Average Average
asmid
ID initiator initiator coding codon termination production production
name
NO sequence sequence frequency sequence Fig 7 Fig 8
PGBFINPLA-
i 8 CACCTCAGCA w.t w.t w=t 100 % 100 %
a
PGBFINPLA-
i b 9 CACCGTCAAA w.t w.t w.t 170 % 130 %
PGBFINPLA-
10 CGCAGTCAAG w.t w.t w.t 130 %
ic
PGBFINPLA-
i d 11 CACCTCAGCA TTCTCTCTC modified TAAATA 170 %
PGBFINPLA-
i 12 CACCGTCAAA TTCTCTCTC modified TAAATA 230 % 240 %
e
PGBFINPLA-
i f 13 CGCAGTCAAG TTCTCTCTC modified TAAATA 260 %
PGBFINPLA-
14 CACCGTCAAA GCTTCCTTC modified TAAATA 230%
ig
pGBFINPLA-
35 US 6,461,837 B1 TTCTCTCTC modified TAAATA 230%
ih
As can be learned from Figure 8, also in a multi-copy (2) situation the
improvement clearly can be found. This indicated clearly how a single
modification or a
10 combination of modifications of the invention, for example a modified
translation initiation
sequence and/or a modified codon usage and/or a modified translation stop
sequence
can be used for improved production of the phospholipase Al in A. niger.
The production of alpha-amylase was measured in all three different A.
nigerFUA
15 transformants. As can be learned from Figure 9, a positive effect of the
use of a modified
translation initiation site (variant 1) on alpha-amylase production can be
observed, using
the alpha-amylase promoter. Additionally, a positive and synergistic effect of
combination
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
71
of a modified translation initiation site (variant 1) with a modified codon
usage and a
modified translation stop sequence on improved alpha-amylase production was
observed. These results indicate clearly the universal effect of the
modification since both
phospholipase production and alpha-amylase production can be improved using a
method of the invention. Additionally, multiple promoters could be improved
using a
modified translation initiation site of the invention. Clearly, these examples
show how a
single or a combination of modifications of the invention, for example a
modified
translation initiation sequence, a modified codon usage and/or a modified
translation stop
sequence can be used for improved production of the alpha-amylase in A. niger
or any
other protein of interest in a filamentous fungus.
CA 02595056 2007-07-17
WO 2006/077258 PCT/EP2006/050398
72
A licant's or a ent's file reference number 2A.<ti3:7W0 International
application No.
INDICATIONS RELATING TO A DEPOSITED MICROORGANISM
(PCT Rule 13bis)
A. The itidications made below relate to the inicroorganism referred to in the
description
Firstly inentioned on page 8 line 29.
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional
sheet
Name of depositary institution
:;15~1'r2.\A;.:.13ilFit'klt; tjOC)F
Address of depositary institution (including postal code and country)
t:p,xsskl:zia.ait 8
P.O. :E3ox 85167
N1.3508.ciD t:,rc:ckit
7.11e Ncfherland,
Date of deposit 10 Aun;ttst 1988 Accession Number CB S :1{3.88
C. ADDITIONAL INDICATIONS (lent~e blank if not applicable) This information is
continued on an additional sheet I I
We inform you that the availability of the microorganism identified above,
referred to Rule 13bis PCT, shall be effected only by issue
of a sample to an expert nominated by the requester until the publication of
the mention of grant of the national patent or, where
applicable, for twenty years from the date of filing if the application has
been refused, withdrawn or deemed to be withdrawn.
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are
n.ot for all designated Siates)
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)
The indications listed below will be submitted to the Intemational Bureau
later (spec fy the general nature of the indications e.g.,
"Accession Nurnber of Deposit")
For receiving Office use only For International Bureau use only
This sheet was received with the international ~ This sheet was received by
the International Bureau
application on:
Authorized officer Authorized officer
Form PCT/RO/134 (July 1992)
